The Life Sciences Report

Novocure Posts Record Q2 Revenue of US$183.6M

Mon, 27 Jul 2026 00:00:00 PST

Source: Streetwise Reports 07/27/2026

Novocure Ltd. (NVCR:NASDAQ) posted record Q2 2026 revenue of US$183.6 million, up 16% year-over-year, and raised full-year guidance to US$710-US$725 million.

An oncology company is catching the attention of life sciences investors after releasing Q2 financial results.

Key Takeaways

Novocure posted record Q2 2026 revenue of US$183.6 million, up 16% year-over-year on 18% patient growth.
Optune Pax received CE Mark approval for pancreatic cancer, with Germany as its first E.U. launch market.
Active patients reached 4,636 on Optune Gio, 285 on Optune Pax, and 207 on Optune Lua as of June 30, 2026.
Gross margin rose to 78% from 74%, helped by a one-time US$4.9 million tariff refund.
Net loss narrowed to US$15.7 million, and adjusted EBITDA turned positive at US$10.8 million.
Novocure raised 2026 guidance to US$710–US$725 million in revenue, with an FDA decision on lung cancer brain metastases expected in Q4 2026.

Optune Pax Earns European Approval

On July 23, 2026, Novocure Ltd. (NVCR:NASDAQ) announced financial results and operational updates from Q2, ending June 30, 2026. "This was our strongest quarter to date, with record net revenues and active patients on therapy," said Frank Leonard, CEO of Novocure. "We continue to launch our therapies in multiple markets, allowing us to bring TTFields therapy to many more patients who can benefit. We are well-positioned to advance our patient-forward mission while driving sustainable growth and making material progress on our path to profitability."

Financial highlights are as follows:

Total net revenues for the quarter were US$183.6 million, an increase of 16% compared to the same period in 2025. This increase was primarily driven by active patient growth globally.

The U.S., Germany, France, and Japan contributed US$103.0 million, US$23.3 million, US$21.3 million, and US$11.8 million, respectively, with other active markets contributing US$18.2 million.

US$2.8 million in net revenue was recognized from one-time benefits in the U.S., Germany, and France.

Net revenue from Optune Lua and Optune Pax in the quarter was US$7.0 million.

Recognized revenue from Optune Lua in the quarter was US$5.4 million. The U.S., Germany, and Japan contributed US$1.9 million, US$1.7 million, and US$1.8 million, respectively.
Recognized revenue from Optune Pax in the quarter was US$1.6 million.

Revenue in Greater China from Novocure's partnership with Zai Lab totaled US$6.0 million.

Gross margin for the quarter was 78% compared to 74% in the prior year. Cost of revenues in the quarter benefited from a one-time US$4.9 million tariff refund.
Research, development, and clinical study expenses for the quarter were US$51.4 million, a decrease of 8% from the same period in 2025. This decrease was primarily driven by lower direct clinical trial expenses from completed trials.
Sales and marketing expenses for the quarter were US$61.7 million, an increase of 8% compared to the same period in 2025. This increase was primarily driven by costs associated with the launch of Optune Pax in the U.S. and Optune Lua in Japan.
General and administrative expenses for the quarter were US$39.9 million, a decrease of 9% compared to the same period in 2025. This decrease was primarily driven by lower share-based compensation expenses.
Net loss for the quarter was US$15.7 million with a loss per share of US$0.13.
Adjusted EBITDA for the quarter was US$10.8 million.
Cash, cash equivalents, and short-term investments were US$440.6 million as of June 30, 2026.

The company's 2026 financial guidance has been updated to reflect a total net revenue of US$710 million to US$725 million, an increase from the previously expected US$690 million to US$710 million. This guidance assumes full-year, mid-to-high single-digit net revenue growth from Optune Gio, favorable foreign exchange rates, and a consistent gross quarterly margin in the mid-70^th percentile.

Operational highlights are as follows:

As of June 30, 2026, there were 5,128 total active patients on TTFields therapy globally.
Optune Gio: As of June 30, 2026, there were 4,636 active patients on Optune Gio, an increase of 11% from the same period in 2025. The U.S., Germany, France, and Japan contributed 2,341, 637, 471, and 553 active patients, respectively, with 634 active patients contributed by other active markets.
Optune Lua: As of June 30, 2026, there were 207 active patients on Optune Lua, an increase of 51% from the same period in 2025. The U.S., Germany, France, and Japan contributed 99, 38, 1, and 64 active patients, respectively, with 5 active patients contributed by other active markets.
Optune Pax: 418 prescriptions for Optune Pax were received in the quarter. As of June 30, 2026, there were 285 active patients on Optune Pax in the U.S.

In an update, Novocure announced that Optune Pax has received the CE Mark for treating adult patients with locally advanced pancreatic cancer of exocrine origin concomitant with gemcitabine and nab-paclitaxel (gem/nab-pac) in accordance with guideline recommendations.

Based in Switzerland, NovoCure is a global oncology company focused on extending survival and improving quality of life in someone the most aggressive cancers. Its proprietary therapy uses Tumor Treating Fields (TTFields), which are approved mainly for glioblastoma, pancreatic cancer, non-small cell lung cancer, malignant pleural mesothelioma, and pleural mesothelioma.

Cancer Cases Rise, Treatment Costs Climb

The global cancer treatment sector, unfortunately, shows no signs of shrinking. A March 26, 2026, article by Kinjel Shah for Yahoo Finance claimed that cancer incidences were rising. He quoted the American Cancer Society as expecting 2.1 million new cancer cases and over 626,000 cancer-related deaths in 2026. However, technology is ever-evolving to keep up with the disease.

Shah wrote, "Emerging technologies such as genomic sequencing, artificial intelligence, and machine learning are accelerating biomarker discovery, enhancing patient stratification, and enabling earlier and more accurate diagnoses. While a universal cure remains out of reach, consistent improvements in survival rates and patient outcomes across multiple cancer types highlight the tangible benefits of these advances, particularly when combined with earlier detection and intervention."

This innovation comes at a price. In February 2026, Keith Speights wrote an article for The Motley Fool discussing rising care costs, stating that cancer treatments in the U.S. cost roughly US$200 billion in 2020 but are expected to increase to more than US$245 billion by 2030.

Many in the pharma sector have been cutting research and development (R&D) costs since the pandemic, citing lower returns. "R&D work on complex, expensive therapies could taper off as companies prioritize already or nearly commercialized drugs, and companies may further consolidate roles to maintain leaner operations," argued BDO at the beginning of 2026. But some companies, like NovoCure, are still investing heavily in drug development. This type of research is necessary. In February 2026, Iqvia discussed the global pharma market projection for 2026, noting that total drug usage is expected to approach four trillion defined daily doses by 2030. They wrote, "The largest drivers of medicine spending growth through the next five years will continue to be the use in developed markets of innovative therapeutics, especially in oncology, immunology, diabetes, and obesity."

Neutral or Buy?

Prior to this news, on July 13, 2026, Jessica Frye of JPMorgan Chase & Co. initiated coverage on the company, issuing a "Neutral" rating with a price target of US$17.00.

On July 23, 2026, Chen Lin of What is Chen Buying? What is Chen Selling? wrote about Novocure, saying: "NVCR exploded today on good earnings data. This was one of my table pounders last year at the tax loss selling season. It was trading at around US$10 today, and it broke US$20. I met NVCR's CEO last year; she was buying the stock and told me how deeply she believed in it. I am not calling NVCR to go back to US$100 or US$200, but US$30-US$50 as it continues to progress is very possible. Maybe we will have a buyout one day. I can take profits and put money into miners at my own pace."

Two separate analysts weighed in on the company on the same day. First, David Nierengarten, Ph.D., of Wedbush reiterated a "Neutral" rating while raising the stock's price target from US$18 to US$20. Nierengarten wrote: "We continue to believe that any substantial growth in the near-term must come from beyond the core GBM franchise, especially given TRIDENT's failure. We remain in a wait-and-see stance as we look for evidence of durable adoption and broader franchise expansion across Pax and Lua."

H.C. Wainwright & Co.'s Emily Bodnar had a more optimistic viewpoint, though, reiterating a "Buy" rating but raising its price target to US$52. Bodnar argued: "We note that this is the second time the company has revised guidance in 2026, demonstrating sustained growth across all marketed therapies, and indicating the strength of the company's commercial capabilities."

FDA Brain Metastases Decision Due Q4

According to the company's investor presentation, in Q4 2026, NovoCure anticipates a decision from the FDA on its premarket approval application for the use of TTFields therapy as a treatment for brain metastases. Finally, to round out the year, the company hopes to complete enrollment for its Phase 3 KEYNOTE D58 trial for newly diagnosed glioblastoma patients.

Ownership & Share Information¹

Novocure Ltd. has a market cap of US$2.32 billion, with 115.82 million shares outstanding. The company's 52-week range is US$9.82-US$20.55. Institutions own 86.68% of shares, and Management & Insiders own 9.95%. The remaining 3.37% of shares are held by Retail. [OWNERSHIP_CHART-10142]

Frequently Asked Questions

Q: What are Tumor Treating Fields (TTFields)?

A: Tumor Treating Fields (TTFields) are a non-invasive cancer treatment that uses low-intensity electric fields to interfere with cancer cell division. The therapy is delivered through adhesive arrays placed on the skin near the tumor and is designed to slow or stop cancer growth while minimizing damage to healthy cells.

Q: What is a CE Mark?

A: A CE Mark is a certification that allows a medical device or certain medicines to be marketed in the European Economic Area (EEA). It shows that the product meets European safety, health, and performance standards, although it is separate from approval by the U.S. Food and Drug Administration (FDA).

Q: What is an FDA premarket approval (PMA)?

A: Premarket Approval (PMA) is the FDA's review process for certain high-risk medical devices. Companies must provide evidence that the device is safe and effective before it can be marketed in the United States. A positive PMA decision is often a major milestone for medical device companies.

Q: What is EBITDA?

A: EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a financial measure that helps investors understand how profitable a company's core business is before accounting for financing costs and certain non-cash expenses.

Q: Why do investors pay attention to quarterly earnings reports?

A: Quarterly earnings reports show how a company performed over the previous three months. Investors use them to evaluate revenue growth, profitability, cash reserves, and business progress, which can influence expectations for the company's future performance.

Important Disclosures:

Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: NVCR:NASDAQ, )

US-Listed Rare Disease Biotech Hit With Full Clinical Hold; Data Unblinding Ahead

Fri, 24 Jul 2026 00:00:00 PST

Source: Dr. Raghuram Selvaraju 07/24/2026

A full FDA clinical hold covers all studies of this hyperphagia candidate, and the company plans to unblind Phase 3 data. An analyst warned the trial "may need to be repeated in its entirety."

On July 20, 2026, analyst Raghuram Selvaraju, Ph.D., of H.C. Wainwright & Co. reiterated a Neutral rating and instituted a US$6.00 per share price target on Aardvark Therapeutics Inc. (AARD:NASDAQ), implying roughly 2% upside from the July 17, 2026, closing price of US$5.86, following the imposition of a full U.S. Food and Drug Administration (FDA) clinical hold on the company's lead asset, ARD-101, and the company's plan to unblind accumulated clinical data.

Clinical Hold and Planned Data Unblinding

Selvaraju reminded investors that the FDA earlier this year placed a full clinical hold on Aardvark's Investigational New Drug (IND) application for ARD-101, tied to the company's previously disclosed voluntary pause in development of the asset. The hold covers all clinical studies conducted under the IND, including the Phase 3 HERO trial (AVK-101-301) evaluating ARD-101 for hyperphagia in patients with Prader-Willi Syndrome (PWS) and the Phase 3 open-label extension (OLE) study (AVK-101-302). Aardvark remains in active discussions with the FDA on resolving the hold and establishing a path forward for the program.

Alongside those discussions, the company intends to unblind clinical data gathered to date across both HERO and the OLE trial in order to weigh the totality of efficacy and safety information and inform its decision on next steps. As of February 27, 2026, 68 patients had been dosed in the randomized controlled HERO trial and 19 patients in the OLE trial. The analyst noted that the near-term unblinding could provide a sufficient basis for lifting the restrictions.

Development Timeline Impact

While the ultimate consequences of the hold cannot be assessed with certainty, Selvaraju speculated that "the HERO trial may need to be repeated in its entirety even under a best-case scenario," though he pointed out that the study's evaluation period runs only 12 weeks. Conservatively, he estimated the hold — even if lifted later this year — could extend the ARD-101 development timeline in PWS by 18 to 24 months. No patients had been dosed in any study of the fixed-dose combination candidate ARD-201, which incorporates ARD-101, but the fate of that combination remains uncertain for as long as the ARD-101 hold stands.

Financial Position and Estimates

Aardvark closed 1Q26 with US$91.2 million in cash, cash equivalents and marketable securities and no debt, resources management expects to fund operations into mid-2027. That equates to US$4.17 in cash per share against a book value of US$3.99 per share, with 21.9 million shares outstanding, a market capitalization of US$128 million, and an enterprise value of US$37 million.

For 1Q26, the company reported research and development expense of US$16.6 million and general and administrative expense of US$5.9 million, producing a net loss of US$21.6 million, or US$0.99 per share. H.C. Wainwright models a full-year 2026 net loss of US$83.1 million, or US$3.80 per share, narrowing to US$51.2 million, or US$1.98 per share, in 2027. No revenue is forecast in either year.

Valuation and Risks

The price target rests on a discounted cash flow methodology applying a 12% discount rate and a 2% terminal growth rate, combined with downwardly revised probabilities of approval for ARD-101 — now 20% in PWS, 10% in hypothalamic obesity (HO), and 5% in mass-market obesity via the ARD-201 combination regimen. Those inputs generate an enterprise value of approximately US$168 million and a total firm value of US$200 million, equating to US$6.00 per share on an assumed 31.9 million fully diluted shares as of mid-2027.

Risks flagged in the report include failure to lift the existing clinical hold, negative results from the Phase 3 HERO trial, inability to secure timely approval in PWS, failure to generate positive data from the Phase 2 HONOR trial in HO, or the Phase 2 ARD-201 studies in mass-market obesity, partnership risks, geopolitical risks, and possible medium-term equity dilution.

Shares of Aardvark Therapeutics traded at US$5.86 as of July 17, 2026, within a 52-week range of US$3.35 to US$17.94. Reaching the US$6.00 target would deliver a return of approximately 2%.

Also referenced in the report was Rhythm Pharmaceuticals, Inc. (RYTM:NASDAQ), which H.C. Wainwright rates Buy with a US$105.00 price target; the stock was priced at US$106.60 with a market capitalization of US$7.31 billion as of July 17, 2026.

Important Disclosures:

This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

( Companies Mentioned: AARD:NASDAQ, )

Antibacterial Drug Partnership Accelerates PolyPid Commercial Path

Thu, 23 Jul 2026 00:00:00 PST

Source: Streetwise Reports 07/23/2026

PolyPid enters a major commercialization deal with Azurity for D-PLEX100 targeting surgical site infections, with upfront payments and milestone potential supporting retail investors watching PYPD progress toward 2027 launch.

Life science investors are taking note of a partnership between PolyPid Ltd. (PYPD:NASDAQ) and Azurity Pharmaceuticals aimed at bringing a new antibacterial drug to market, meant to prevent infection on abdominal surgical sites.

Pharma Market Opportunity Sets Stage for Specialized Therapies

The broader pharmaceutical sector continues to see strong demand for innovative treatments that address clear patient needs. In February 2026, Iqvia discussed the global pharma market projection for 2026, noting that total drug usage is expected to approach four trillion defined daily doses by 2030. They wrote, "The largest drivers of medicine spending growth through the next five years will continue to be the use in developed markets of innovative therapeutics, especially in oncology, immunology, diabetes, and obesity."

Pharma sector funding fell between 2024 and 2025, according to a March 26, 2026, article for Fierce Biotech by Nick Paul Taylor. He wrote that pharma funding had fallen from 2024 but noted that, "2025 was still the third-best year of the past decade. Similarly, overall funding was well above the pre-pandemic norm and only topped by 2020, 2021, and 2024."

BCG talked about trends biopharma companies need to be aware of in 2026 in order to stay competitive, saying, "Near term, companies need to continue to innovate to decrease the complexity and cost of these therapies, and governments can find ways to incentivize and pay for them. The longer-term challenge for companies is to factor operational and economic considerations into R&D decision making earlier, ensuring that trial designs match real-world usage, indication sequences match opportunity, and endpoints enable market access."

Why PolyPid Stands Out Through Strategic Partnership

On July 21, 2026, PolyPid announced that the company had entered into an agreement with Azurity for the commercialization of D-PLEX₁₀₀— a drug intended to prevent surgical site infections — in both the U.S. and Canada. The agreement states that PolyPid will receive an upfront payment of US$15 million upon signing, with an additional US$15 million payable upon United States Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) for the medication. Further, the company could earn up to US$300 million in additional regulatory, development, and sales-based milestone payments. As part of the collaboration, the companies may agree to jointly pursue potential label expansion of the drug into additional SSI (surgical site infections) to include more than abdominal sites.

Unique Business Model and Key Catalysts

Under the agreement, PolyPid will manufacture the drug, while Azurity will be responsible for commercial distribution. PolyPid is an Israel-based biopharma company that focuses on developing long-acting, controlled-release drugs designed to address unmet medical needs across a diverse pipeline that includes surgical care, metabolic diseases, and more. Dikla Czaczkes Akselbrad, CEO of PolyPid, said in the release: " This partnership is a defining step in PolyPid's transition into a commercial-stage company, and Azurity is the right partner to bring D-PLEX₁₀₀ to U.S. and Canadian patients, hospitals, and surgeons. We believe that Azurity's first-in-class commercial model and demonstrated commercial execution will be invaluable in expanding access to D-PLEX₁₀₀, if approved. Importantly, this collaboration represents a meaningful validation of our unique platform, and allows us to fully realize the U.S. and Canadian commercial value of D-PLEX₁₀₀ while putting us in a position of financial strength to continue investing in our Kynatrix technology, pipeline, and the next generation of therapies."

For Azurity, CEO Ronald Scarboro said: "At Azurity, we believe meaningful innovation is measured by the difference a therapy makes in the realities of patient care. D-PLEX₁₀₀ is a differentiated therapy addressing an important unmet need, and we are excited to partner with PolyPid to help bring it to patients in the United States and Canada, if approved. Our commercial model was built to support specialized therapies like this — connecting the right treatment to the right healthcare professionals and patients through efficient, focused execution. Together, we believe we can expand access to an important new option while exploring opportunities to broaden its impact in the years ahead."

Key Investor Takeaways

PolyPid signed an exclusive deal with Azurity Pharmaceuticals to commercialize D-PLEX100 in the U.S. and Canada.
Azurity will fund further clinical trials to potentially expand D-PLEX100's label beyond abdominal surgery, while PolyPid handles manufacturing and supply.
The deal follows positive Phase 3 SHIELD II results, which hit the primary endpoint and showed a 60% relative risk reduction in infection incidence.
A U.S. launch is targeted for the first quarter of 2027, with PolyPid retaining global rights outside the U.S. and Canada.
Analysts from Roth and H.C. Wainwright issued Buy ratings with price targets of US$9.00 and US$13.00, respectively.

Analyst Views and Upcoming Regulatory Timeline

Two separate analysts tackled Polypid's news after its release. On July 21, 2026, Boobalan Pachaiyappan, Ph.D., of Roth reiterated a "Buy" rating for the stock, with a price target of US$9.00. Regarding the exclusive commercialization and licensing partnership, Pachaiyappan wrote: "Is Azurity a right fit for PolyPid — we think yes! For context, Azurity is a specialty pharma with a proven hospital presence, given their focus on at least 10 therapeutic areas (including anti-infectives, which is where D-PLEX100 would fit in). Notably, D-PLEX100's de-risked Ph3 data in surgical site infections associated with colorectal cancer surgeries and first-in-class potential are squarely aligned with Azurity's business model, focusing on commercializing medicines in underserved patients."

On the same day, Brandon Folkes of H.C. Wainwright & Co. issued a "Buy" rating, with a price target of US$13.00. PolyPid's agreement with Azurity has helped put some of Folkes' concerns to rest, as he wrote: "The partnership removes a key uncertainty around the D-PLEX₁₀₀ commercial strategy. We have previously viewed a U.S. partnership as an important catalyst for PYPD, particularly given the longer institutional sales cycles that can accompany hospital products. PYPD had also been operating with a relatively limited cash runway, and we viewed a meaningful upfront payment as important to allowing the company to invest behind the broader pipeline without having to fund a U.S. commercial organization itself."

The company expects the FDA to accept its NDA for D-PLEX₁₀₀in August 2026. According to PolyPid's investor presentation, the company hopes for a PDUFA date in early 2027 and expects to grow its Pipeline with Kynatrix, enabling expansion into additional high-value indications beyond the lead program.

Share Structure and Ownership Details

PolyPid Ltd. has a market cap of US$77.71 million, with 19.17 million shares outstanding. The company's 52-week range is US$3.06-US$5.73.

¹Institutions own 34.85% of shares, while Strategic Investors own 5.78%. Management & Insiders own 15.45% of shares, and the remaining 43.92% of shares are held by Retail. [OWNERSHIP_CHART-11650]

Common Questions from Investors

Q: What is a Phase 3 clinical trial?

A: A Phase 3 clinical trial is one of the final stages of testing before a company asks regulators to approve a new medicine. It typically compares a new treatment with the current standard of care in a large group of patients to confirm that it is safe and effective.

Q: What is a New Drug Application (NDA)?

A: A New Drug Application (NDA) is the formal request a pharmaceutical company submits to the U.S. Food and Drug Administration (FDA) asking for permission to sell a new drug. The FDA reviews the clinical trial data, manufacturing process, and safety information before deciding whether to approve the treatment.

Q: What are surgical site infections?

A: Surgical site infections (SSIs) are infections that develop in the area of the body where surgery was performed. They can range from mild skin infections to more serious complications that require additional treatment, longer hospital stays, or even more surgery.

Q: Why do biotech companies partner with larger pharmaceutical companies?

A: Many biotech companies specialize in discovering and developing new medicines, but don't have the resources to manufacture, market, and distribute them on a large scale. Partnering with an established pharmaceutical company allows a promising treatment to reach patients more efficiently while helping the biotech company fund future research.

Q: What is a PDUFA date, and why do investors watch it?

A: A PDUFA date is the deadline by which the FDA aims to decide whether to approve a new drug after reviewing its application. Investors closely follow these dates because an approval can open the door to commercial sales, while a delay or rejection can significantly affect a company's outlook.

The partnership provides PolyPid with immediate capital and a clear path to potential U.S. and Canadian commercialization while preserving rights elsewhere, positioning the company for measured growth in a competitive sector.

Important Disclosures:

Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: PYPD:NASDAQ, )

Biotech Advances VOXZOGO Toward Landmark US FDA Approval

Mon, 20 Jul 2026 00:00:00 PST

Source: Streetwise Reports 07/20/2026

BioMarin Pharmaceuticals Inc.'s (BMRN:NASDAQ) supplemental New Drug Application seeking traditional approval for VOXZOGO (vosoritide) to treat children with the genetic bone-growth disorder achondroplasia has been accepted.

BioMarin Pharmaceuticals Inc. (BMRN:NASDAQ) announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) seeking traditional approval for VOXZOGO® (vosoritide) to treat children with the genetic bone-growth disorder achondroplasia, according to a July 13 release.

The FDA assigned the application a Prescription Drug User Fee Act (PDUFA) target action date of Feb. 28, 2027.

"This submission for VOXZOGO is supported by the largest body of evidence for any medicine in achondroplasia, reflecting BioMarin's long-standing commitment to advancing the science of skeletal growth," said BioMarin Executive Vice President and Chief Research and Development Officer Dr. Greg Friberg. "The clinical data demonstrate meaningful improvements across multiple skeletal growth-related measures beyond annualized growth velocity in children with this condition. If approved, VOXZOGO would be the first therapy for achondroplasia to convert from accelerated approval to traditional approval based on a comprehensive clinical data package, including adult height outcomes and other clinical measures evaluated over extended follow-up."

The application is backed by extensive long-term safety and efficacy results from three ongoing studies, identified as 111-205, 111-208, and 111-302. BioMarin said the research demonstrated clinically meaningful improvements in growth as well as important skeletal growth measures, including body proportionality and arm span. The submission also contains the longest-running safety and efficacy dataset assembled for any therapy studied in achondroplasia.

VOXZOGO received accelerated FDA approval in 2021 through a pathway intended to speed patient access to treatments based on measures that are reasonably likely to predict clinical benefit. BioMarin said the current filing is designed to satisfy the postmarketing requirement by confirming the benefit and securing full approval through long-term data from the three ongoing studies, which continue to show meaningful improvements in growth and skeletal health outcomes for children with achondroplasia.

More than 80% of Affected Children Born to Average-Height Parents

Achondroplasia is the most common form of skeletal dysplasia that causes disproportionate short stature. The condition develops when endochondral ossification slows, leading to abnormal development of the long bones, spine, face, and base of the skull. It is caused by a mutation in the FGFR3 gene, which normally acts as a regulator of bone growth.

BioMarin said more than 80% of children with achondroplasia are born to parents of average height, with the condition resulting from a spontaneous genetic mutation. The disorder occurs in approximately one out of every 25,000 live births worldwide. The company is studying VOXZOGO in children whose growth plates remain "open," generally those younger than 18 years old, a population representing about 25% of people with achondroplasia. BioMarin added that further information about its clinical studies involving achondroplasia, hypochondroplasia, and other skeletal disorders is available through its clinical trials website.

According to BioMarin, VOXZOGO is a C-type natriuretic peptide (CNP) analog that targets the biological pathway downstream of FGFR3 to stimulate endochondral bone growth, which is impaired in children with achondroplasia because of a gain-of-function mutation in the FGFR3 gene. The company said the therapy is the only approved medicine that supports growth in children with achondroplasia beginning at birth, and international treatment guidelines recommend starting therapy as early as possible.

Since its initial approval in 2021, VOXZOGO has been used to treat more than 5,000 infants and children in over 50 countries. BioMarin said it continues to study the therapy's effects on clinically important measures, including arm span, tibial bowing, body proportionality, spinal morphology, including spinal stenosis, and quality of life.

The company said VOXZOGO is approved in the United States, Japan, and Australia to increase linear growth in children of all ages with achondroplasia whose growth plates remain open. In the European Union, the treatment is approved for children four months of age and older whose growth plates have not closed, provided genetic testing confirms the diagnosis. In the United States, the indication remains under accelerated approval based on improved annualized growth velocity, with continued approval dependent on confirmatory evidence of clinical benefit. BioMarin said it plans to meet that postmarketing requirement by comparing data from its ongoing open-label extension studies with available natural history data.

BioMarin described itself as a global biotechnology company focused on developing treatments for rare diseases caused by genetic conditions. The San Rafael, California-based company said it has concentrated on advancing medicines that address genetically defined disorders since its founding in 1997.

The company said its portfolio includes nine commercial therapies supported by a broad pipeline of clinical and preclinical drug candidates. BioMarin added that its research and development strategy emphasizes innovative approaches to drug discovery with the goal of creating category-defining therapies that deliver meaningful benefits for patients living with rare genetic diseases.

Therapy Converting From Accelerated to Traditional Approval

According to an updated research note on July 14 by H.C. Wainwright & Co. Analyst Mitchell S. Kapoor, the acceptance by the FDA was "anticipated."

"If approved, VOXZOGO would be the first therapy for ACH to convert from accelerated approval to traditional approval based on a comprehensive clinical data package, including adult height outcomes and other clinical measures evaluated over extended follow-up," Kapoor wrote.

The analyst said the prospect of VOXZOGO receiving full approval aligns with existing expectations and is not expected to materially change the competitive outlook as rival programs continue to advance. Attention is now focused on BioMarin's expected 2027 guidance for hypochondroplasia (HCH), quarterly trends in VOXZOGO patient starts, treatment persistence, and potential pressure on new patient starts and treatment switching in the United States following the introduction of Ascendis Pharma's YUVIWEL.

The analyst maintained a Neutral rating on BioMarin shares along with a 12-month price target of US$50.

Using a discounted cash flow model with a 10% discount rate and a 1% terminal growth rate, Kapoor estimated BioMarin's enterprise value at about US$12.3 billion. The report said the company is expected to have roughly US$4.3 billion in debt after accounting for convertible debt following the closing of the Amicus transaction. Based on an estimated 192 million fully diluted shares outstanding and projected year-end 2026 cash and equivalents of about US$2.1 billion, the analyst arrived at the US$50 12-month price target.

The report said key risks include slower-than-expected commercial adoption of BioMarin's products, particularly VOXZOGO, delays in regulatory approvals for late-stage pipeline candidates, and the possibility of long-term shareholder dilution.

Co. Holds Advantage Over Competitors, Analyst Says

On May 21, Wedbush Analyst Yun Zhong wrote an updated note on the company, rating it Outperform with a US$94 per share price target.

The analyst said positive Phase 3 results in hypochondroplasia should allow BioMarin to expand the potential patient population for VOXZOGO and strengthen the therapy's leadership position in skeletal disorders. The report highlighted a placebo-adjusted increase of 2.33 centimeters per year in annualized growth velocity after 52 weeks, exceeding the improvement previously reported in the Phase 3 achondroplasia study.

The report suggested the successful trial could support development in additional skeletal disorders, which together could represent a commercial opportunity more than 10 times larger than the combined markets for achondroplasia and hypochondroplasia.

Zhong noted that hypochondroplasia may be more common than previously recognized because the condition is often underdiagnosed due to its relatively subtle clinical features. While earlier thinking suggested disproportionate short stature was the primary concern, unlike achondroplasia, which is associated with complications such as foramen magnum stenosis, sleep apnea, and spinal stenosis, the analyst cited a retrospective real-world matched cohort study conducted by BioMarin showing significantly higher rates of respiratory, cardiovascular, orthopedic, and mental health-related comorbidities among patients with hypochondroplasia. The report also noted that these patients may face an increased risk of temporal lobe epilepsy and learning disabilities.

The analyst said BioMarin currently holds an advantage over competitors in the hypochondroplasia market, although rival programs continue to advance.

The Catalyst: Diagnostic Methods More Accurate

The global skeletal dysplasia market size was estimated at US$3.2 billion in 2025 and is projected to reach US$6.9 billion by 2035, growing at a CAGR of 8.1% from 2026 to 2035, according to a report by Vantage Market Research.

The report said the market continues to gain momentum as healthcare providers improve recognition of rare genetic bone disorders, diagnostic methods become more accurate, and targeted therapies become increasingly integrated into specialized treatment programs.

According to the report, the sector combines elements of rare disease therapeutics and precision medicine, with advances in treatment, supportive regulatory policies, and long-term patient care strategies serving as the primary factors shaping its long-term growth and strategic significance.

"The skeletal dysplasia market occupies a highly specialized niche within the broader rare disease therapeutics ecosystem, characterized by low patient volumes but high clinical complexity and lifetime care requirements," the report said. "The market's role is defined by its integration across diagnosis, therapeutic intervention, and long-term disease management, where multidisciplinary care models are essential. Unlike high-prevalence therapeutic areas, this market operates under a precision-driven paradigm, where each intervention is closely aligned with genetic subtypes and disease severity."

This market reflects an evolving maturity profile, transitioning from symptomatic management toward disease-modifying approaches. The shift is driven by advances in genetic research and regulatory frameworks that incentivize orphan drug development. For CXOs, the market represents a convergence of scientific innovation and reimbursement complexity, where success depends on aligning clinical efficacy with payer acceptance. The strategic relevance lies in navigating fragmented patient populations while building scalable therapeutic and diagnostic solutions that can sustain long-term engagement.

The report said the market is evolving beyond treatments that primarily manage symptoms and is increasingly focused on therapies designed to modify the underlying disease. It attributed this transition to advances in genetic research and regulatory policies that encourage the development of orphan drugs.[OWNERSHIP_CHART-4194]

According to the report, the market presents both opportunities and challenges for healthcare executives by combining rapid scientific progress with increasingly complex reimbursement requirements. The report said long-term success will depend on demonstrating strong clinical outcomes that satisfy payers while developing scalable therapeutic and diagnostic platforms capable of serving fragmented patient populations over time.

Meanwhile, the global genetic disorders market size was US$15.95 billion in 2023 and is expected to surpass around US$50.61 billion by 2033, growing at a CAGR of 12.24% from 2024 to 2033, according to BioSpace. The genetic disease market is expected to grow with the identification of 6,000-8,000 rare diseases (RDs), of which approximately 80% are genetic and 50-75% initiate from early childhood.

Ownership and Share Information1

BioMarin Pharmaceutical Inc. has a market cap of CA$11.52 billion, with 193.28 million shares outstanding. The company's 52-week range is US$49.26-US$66.28.

Institutions own 95% of shares, while management and insiders own nearly 2% of shares, and retail owns the rest.

Common Investor Questions

What did the FDA do? It accepted BioMarin's supplemental New Drug Application seeking full (traditional) approval of VOXZOGO for children with achondroplasia.

When will the FDA decide? The PDUFA target action date is Feb. 28, 2027.

What is achondroplasia? The most common form of skeletal dysplasia, causing disproportionate short stature, is caused by an FGFR3 gene mutation. It occurs in about 1 in 25,000 births, and over 80% of cases arise spontaneously in children of average-height parents.

What's the market opportunity? The global skeletal dysplasia market is projected to grow from US$3.2B (2025) to US$6.9B by 2035 (8.1% CAGR).

Important Disclosures:

Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: BMRN:NASDAQ, )

Satellos Bioscience Delivers Promising DMD Data With Fast Track Win

Fri, 10 Jul 2026 00:00:00 PST

Source: Streetwise Reports 07/10/2026

Satellos Bioscience reports strong six-month TRAILHEAD data for SAT-3247 in DMD adults, secures Fast Track status, and advances pediatric trials amid growing muscle disease market opportunity.

The global market for muscle wasting disorders is expanding rapidly as aging populations and rising chronic disease rates increase demand for effective treatments. Investors tracking rare disease biotechs are focusing on companies like Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) that combine novel mechanisms with clear regulatory momentum.

Satellos stands out because its lead candidate, SAT-3247, uses an oral small-molecule approach to restore muscle repair signals rather than relying solely on gene replacement or exon skipping. Recent interim results from the TRAILHEAD study in adults with Duchenne muscular dystrophy (DMD) showed consistent stability or improvement across multiple measures, positioning the company for potential accelerated development, according to a July 8 release.

Why the Latest Data Matters for Investors

Four adults aged 21 to 28 who had completed an earlier Phase 1a/b study received SAT-3247 for an average of 186 days. Every participant showed a decline in muscle fat fraction on MRI, averaging a 3.7 percent improvement.

Upper-limb effort measured by TE99C rose about 34 percent, while strength measures, including handgrip, remained stable at the higher levels achieved in the prior study. Creatine kinase levels fell 38 percent on average, and quality-of-life scores improved. The drug maintained a favorable safety profile with full compliance.

Key Investor Takeaways

SAT-3247 produced measurable reductions in muscle fat fraction, a key MRI endpoint, in adults with advanced DMD, where improvement is difficult to achieve.
Multiple secondary measures, including effort, strength, CK levels, and function, remained stable or improved, supporting biological activity.
Fast Track designation from the FDA adds regulatory advantages that could shorten development timelines for this oral therapy.
Upcoming BASECAMP data in younger patients with greater remaining muscle mass could provide stronger efficacy signals.
Analyst price targets range from US$11 to US$23, reflecting optimism around clinical catalysts through year-end.
The broader DMD drugs market is projected to grow at a 16.8 percent CAGR through 2030, offering a sizable commercial opportunity.

Fast Track Designation Accelerates Path Forward

In June, Satellos announced that SAT-3247 received FDA Fast Track designation for DMD. This status enables more frequent agency interactions, rolling review of applications, and potential priority review or accelerated approval pathways.

Combined with existing Orphan Drug and Rare Pediatric Disease designations, the designation reinforces the program's momentum as the company prepares to open U.S. sites for TRAILHEAD and complete enrollment in the pediatric BASECAMP study during the third quarter.

Analyst and Market Reaction

According to Nick Paul Taylor, writing for Fierce Biotech on July 8, Guggenheim Securities analysts described the six-month data as intriguing and consistent across endpoints. They noted that other DMD therapies have only slowed fat deposition, whereas SAT-3247 produced an actual reduction in fat fraction.

The firm highlighted the results as a positive signal for the upcoming BASECAMP trial in boys aged 7 to 10. One-year TRAILHEAD data and initial BASECAMP topline results are both expected in the fourth quarter, providing near-term catalysts.

Market Opportunity Supports Long-Term Growth

The global muscle wasting disorders market is forecast to expand from US$12.7 billion in 2022 to more than US$45.4 billion by 2031 at a 15.1 percent CAGR, according to a report by Transparency Market Research.

Within this space, the DMD drugs segment alone is projected to grow from US$3.47 billion in 2023 to US$9.91 billion by 2030 at a 16.8 percent CAGR, Grand View Research said. North America currently accounts for the largest share, driven by molecular therapies and expanding distribution channels. Rising prevalence estimates of roughly 1 in 3,500 male births for DMD, combined with greater awareness and funding, continue to support demand for new regenerative approaches.

Ownership Structure and Upcoming Milestones¹

Satellos Bioscience Inc. has a market capitalization of CA$185.15 million based on 20.83 million shares outstanding. The 52-week trading range is CA$4.64 to CA$13.39. [OWNERSHIP_CHART-11545]

Institutions hold 50.63 percent, insiders and management own 6.51 percent, and retail investors account for the remaining 42.86 percent.

With multiple clinical readouts scheduled for the fourth quarter and continued regulatory engagement, the company offers a defined set of catalysts for investors monitoring the DMD space.

Common Questions from Investors

What is SAT-3247? An oral small-molecule drug designed to restore muscle stem cell signaling and promote repair in degenerative muscle diseases such as DMD.

How does Fast Track designation help? It provides more frequent FDA meetings, rolling review of submissions, and eligibility for accelerated approval or priority review, potentially shortening timelines.

When will the next data be available? One-year results from the adult TRAILHEAD cohort and initial topline data from the pediatric BASECAMP study are both expected in the fourth quarter of 2026.

What is the current analyst consensus? Recent ratings include Strong Buy from Guggenheim, Leerink, H.C. Wainwright, and Cantor Fitzgerald, with price targets between US$11 and US$23.

What are the main risks? Clinical development carries inherent uncertainty, and small early-stage studies may not predict larger trial outcomes or regulatory success.

Important Disclosures:

Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: MSCL:TSX;MSLE:NASDAQ, )

Biotech With Muscle Disease Drug Uncovers Results in Trial Data

Thu, 09 Jul 2026 00:00:00 PST

Source: Streetwise Reports 07/09/2026

Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) shares promising data from its study evaluating a drug to fight Duchenne muscular dystrophy. Find out why at least one expert says the study "delivered" great data.

Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) shared promising six-month interim data from its TRAILHEAD study evaluating the investigational drug SAT-3247 in adults with Duchenne muscular dystrophy (DMD), according to a July 8 release.

The participants, four adults aged between 21 and 28 who had previously completed the Phase 1a/b CL-101 study, exhibited reduced muscle fat fraction, increased total effort, stable strength, lower CK levels, and a safety and tolerability profile consistent with prior data, said the clinical-stage biotech company focused on developing novel therapies for degenerative muscle diseases.

"Adults living with DMD represent one of the most challenging populations in which to evaluate treatment effects because of advanced muscle loss, fat infiltration, and reduced muscle stem cell reserves," David Geffen School of Medicine Professor of Neurology and Pediatrics at UCLA Dr. Perry Shieh said. "Despite meaningful advances with exon-skipping therapies and gene therapy, DMD remains a disease for which there is no cure."

The doctor continued, "Adults living with DMD continue to experience progressive muscle loss, making improvement in fat fraction and total effort promising, and stability across multiple clinically relevant measures as observed with SAT-3247 treatment makes these findings potentially clinically meaningful. Although the study is small, the consistency across measures of strength, muscle composition, effort, quality of life and safety is highly encouraging for the ongoing clinical evaluation of SAT-3247 in TRAILHEAD and BASECAMP."

The study's data highlights include SAT-3247's well-tolerated nature, consistent safety profile, and 100% compliance over an average of 186 days of drug exposure, the release noted. MRI assessments showed all four participants experienced a decline in muscle fat fraction, with an average improvement of 3.7%.

Additionally, there was an approximate 34% increase in TE99C, a measure of maximum effort in the upper limbs, suggesting enhanced upper limb activity, according to the company. Stability was observed across all measures of upper extremity strength, including handgrip and handheld dynamometry of the elbow and shoulder, maintaining the near-doubling of handgrip strength reported during the CL-101 study through to the end of the six-month follow-up.

"We are excited by the six-month interim TRAILHEAD data showing consistent stability or improvement across multiple clinically relevant measures following SAT-3247 treatment in adults living with DMD," Satellos Co-Founder and Chief Executive Officer Frank Gleeson said. "We believe these findings continue to show the biological activity of SAT-3247 and are potentially encouraging for BASECAMP, where a pediatric DMD population with greater remaining muscle mass may offer additional opportunity to demonstrate the clinical potential of SAT-3247. We remain on track to complete enrollment in BASECAMP and to initiate US clinical trial sites for TRAILHEAD in the third quarter of this year."

Further supporting measures from the study include a 38% decline in mean CK from the CL-101 baseline through month six in TRAILHEAD, and improvements or stability in mean PUL2.0 scores, which assess upper limb function, the company said. Additionally, mean PedsQL-MFS scores, a quality-of-life measure for adults, increased by 6.94 points from the baseline to month six in TRAILHEAD.

Satellos said it remains on track to complete enrollment in BASECAMP and to initiate U.S. clinical trial sites for TRAILHEAD in the third quarter of this year, continuing to explore the potential of SAT-3247 in treating DMD.

Treatment Receives Fast Track Designation

In June, Satellos announced a significant regulatory milestone as its SAT-3247 treatment for DMD received Fast Track designation from the U.S. Food and Drug Administration (FDA). This designation is crucial as it is intended to hasten the review process for drugs that address serious health conditions and fill unmet medical needs. With Fast Track status, Satellos may benefit from more frequent FDA interactions, a rolling review of its marketing applications, and the possibility of accelerated approval and priority review.

SAT-3247, described as an oral, small-molecule drug, represents a potentially innovative approach to treating skeletal muscle loss associated with DMD.

"Fast Track designation represents an important validation of SAT-3247 and our commitment to transforming the treatment landscape for Duchenne," Gleeson said at the time. "Together with our Orphan Drug and Rare Pediatric Disease designations, this recognition further strengthens the momentum behind our clinical program."

He emphasized the unique regenerative mechanism of SAT-3247, which aims to re-establish the biological signals necessary for effective muscle repair and regeneration.

Gleeson also highlighted the company’s ongoing efforts to advance its Phase 2 studies and its commitment to continuous engagement with the FDA to progress SAT-3247's development for the benefit of individuals and families dealing with Duchenne.

Report: Analyst Says Results Are 'Impressive'

According to Nick Paul Taylor writing for Fierce Biotech on July 8, The DMD data impressed Guggenheim Securities analysts, who called the results intriguing and consistent.

“In our view, the consistency of effect across this diverse set of endpoints is suggestive of a true drug effect — an impressive feat given the advanced disease state of these patients,” the analysts said in a note to investors. “To the best of our knowledge, other DMD therapies have only been able to slow the rate of fat deposition but did not result in a reduction in FF.”

During a recent call with investors, Wildon Farwell, M.D., Chief Medical Officer at Satellos, highlighted the encouraging changes observed in muscle fat fraction (FF) as measured by MRI scans, according to the report by Taylor. This measure is the primary endpoint of the Trailhead phase 2 trial, which Satellos is currently conducting to evaluate the efficacy of SAT-3247 in adults with Duchenne muscular dystrophy (DMD). Farwell noted that increases in FF are typically associated with a loss of function in DMD patients, underscoring the significance of these findings.

Analysts from Guggenheim have expressed optimism about the implications of the adult data for the upcoming Basecamp study, which will involve boys aged 7 to 10 years, Taylor wrote. They regard the adult study results as a promising indicator for the pediatric trial. Satellos has announced plans to complete enrollment for the Basecamp study in the third quarter and expects to release initial topline data from the study in the fourth quarter. Additionally, one-year data on the four adult patients participating in the Trailhead trial are also scheduled to be released in the fourth quarter, providing further insights into the long-term effects of SAT-3247.

'MSLE Delivered!'

According to Chen Lin of What is Chen Buying? What is Chen Selling? in a July 8 update, "MSLE delivered!"

"The data couldn’t be better in my opinion," Chen wrote. "Not only did two patients improve significantly in the MRI, all the four patients are moving in the right direction. I believe if MSLE can deliver good data of the basecamp Q4 and continue improving trailhead data, accelerated approval should be achievable."

Chen said he sees the company hitting US$100 per share "by the end of the year if the data are as good as we hope."

"I have been there before and can see this happening if the data are positive," the expert said. "The market is giving less than 10% chance of success, I believe it is very mispriced."

On February 10, 2026, Zacks Research gave Satellos a "Hold" rating but did not provide a price target.

On March 11, 2026, Yanni Souroutzidis of Cantor Fitzgerald & Company gave the company a "Strong Buy" rating but did not provide a price target.

On March 30, 2026, Arthur He of H.C. Wainwright & Co. gave Satellos a "Strong Buy" rating and a price target of US$11.

On April 6, 2026, Joseph P. Schwartz of Leerink Partners gave the company a "Strong Buy" rating, with a price target of US$20.

Later in the month, on April 28, 2026, Debjit Chattopadhyay of Guggenheim Securities gave the company a "Strong Buy" rating, with a price target of US$23.

Finally, on May 21, 2026, Tania Gonsalves of Canaccord Genuity gave the company a "Buy" rating, with a US$13.68 price target.

The Catalyst: Increase in Cases to Lead to Market Growth

The global muscle wasting disorders market is poised for significant growth, with its valuation expected to rise from US$12.7 billion in 2022 to over US$45.4 billion by 2031, advancing at a compound annual growth rate (CAGR) of 15.1% from 2023 to 2031, according to a report by Transparency Market Research. This market encompasses conditions characterized by the progressive degeneration of muscle mass and function, and it is witnessing substantial advancements due to ongoing research and development efforts.

Analysts predict that the muscle wasting disorders market will experience steady growth in the coming years, driven by an increase in the prevalence of these disorders. Factors contributing to this rise include aging populations, the growing incidence of chronic diseases, neurological issues, and lifestyle choices. As the global population ages and chronic diseases become more prevalent, the number of individuals affected by muscle wasting disorders is expected to increase significantly, thereby boosting the demand for effective treatment solutions.

Recent breakthroughs in therapy development, including pharmaceuticals, gene-based interventions, and regenerative medicine, have brought new hope to patients and are expected to propel market growth, Transparency's report said. Additionally, the approval of medications by regulatory bodies such as the FDA plays a crucial role in advancing the market by allowing new treatments to reach patients, the research firm said.

The market benefits from increased awareness of muscle wasting disorders and enhanced government investments in research and development. According to the National Center for Biotechnology Information (NCBI), the global prevalence of muscular dystrophy (MD) is estimated at 16.1 individuals per 100,000 people, with DMD being the most common form.

DMD, which affects approximately 1 in every 3,500 live male births, involves a mutation in the gene that encodes dystrophin, a protein essential for maintaining muscle cells' integrity.

The global DMD drugs market is experiencing significant growth, with its valuation projected to rise from US$3.47 billion in 2023 to US$9.91 billion by 2030, marking a CAGR of 16.8% from 2024 to 2030, Grand View Research said. This growth is primarily driven by the increasing prevalence of DMD, advancements in genetic research, and enhanced funding for research and development.[OWNERSHIP_CHART-11545]

In 2023, North America held the largest revenue share of the global DMD drugs market, accounting for 45.0%. Within the market, molecular-based therapies led the treatment segments, representing 42.0% of the market's revenue share. Additionally, the online pharmacies segment is anticipated to be the fastest-growing distribution channel, with a projected CAGR of 16.7% during the forecast period.

The expansion of the DMD drugs market is supported by significant advancements in gene editing and molecular biology technologies, which have led to more precise and efficient therapies. Financial backing from governments, non-profit organizations, and pharmaceutical companies is crucial in fostering ongoing research and development in this field.

There is a growing focus on drug development for DMD, highlighting the efforts to develop clinical solutions. Collaborations between biotech companies and universities are pivotal in advancing state-of-the-art treatments. Furthermore, efforts from major pharmaceutical and healthcare institutions to expedite the approval of orphan drugs are contributing to market growth and improving treatment options for DMD patients.

Ownership and Share Information¹

Satellos Bioscience Inc. has a market cap of CA$185.15 million, with 20.83 million shares outstanding. The company's 52-week range is CA$4.64-CA$13.39.

Institutions own 50.63%, with Management and Insiders owning 6.51%. The remaining 42.86% of shares are held by Retail.

Important Disclosures:

Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: MSCL:TSX;MSLE:NASDAQ, )

NASDAQ-Listed Duchenne Muscular Dystrophy Drugmaker Wins FDA Filing Acceptance Despite Confirmatory Trial Miss

Wed, 08 Jul 2026 00:00:00 PST

Source: Mitchell Kapoor 07/08/2026

The FDA accepted the company's morpholino oligomer filings with a February 2027 PDUFA date, but a missed confirmatory trial endpoint clouds its path to full approval.

On July 1, 2026, Mitchell S. Kapoor and Raghuram Selvaraju, Ph.D., of H.C. Wainwright & Co. reiterated a Sell rating and US$5.00 price target onSarepta Therapeutics Inc. (SRPT:NASDAQ), implying roughly 72% downside from the June 30, 2026 closing price of US$17.97, following the FDA's acceptance of the company's phosphorodiamidate morpholino oligomer (PMO) filings, which the analysts argue does not automatically translate into full approvals given that the confirmatory ESSENCE trial missed its primary endpoint.

Filing Acceptance Seen as Procedural, Not a Regulatory Signal

The FDA's acceptance sets a February 28, 2027, PDUFA date, which the analysts say removes near-term administrative risk while creating a defined binary catalyst on PMO durability. They caution against reading the decision as a favorable regulatory indication: "We do not view this as regulatory momentum or hints of favorable regulatory opinions for the PMO franchise."

Although the stock closed up roughly 6% on the news versus a flat XBI (NYSE Arca: XBI), the analysts interpret the acceptance as a "procedural checkpoint," noting that the FDA's agreement to review the package is not a suggestion that the trial results plus real-world evidence (RWE) are sufficient to convert the accelerated approvals into traditional ones.

They emphasize that no DMD PMO has achieved primary efficacy in Phase 3 and converted to a traditional approval. H.C. Wainwright will maintain its bearish stance absent real quarter-over-quarter ELEVIDYS revenue recovery, more definitive siRNA translation in late 2026, or a stronger signal that the FDA is comfortable converting the accelerated approvals despite the failed intent-to-treat (ITT) result.

ESSENCE Endpoint Miss Remains the Core Overhang

ESSENCE was a 225-patient, randomized, double-blind, placebo-controlled Phase 3 trial in 6- to 13-year-old DMD patients amenable to exon 45 or exon 53 skipping. The primary endpoint — four-step ascend velocity at Week 96 — numerically favored treatment but missed statistical significance, with a least squares mean difference of 0.06 steps/second and p=0.309.

A COVID-exclusion analysis that removed 23 patients, roughly 10% of the ITT population, improved the delta to 0.12 steps/second at p=0.050. The analysts view this as a plausible regulatory argument that nonetheless leaves the primary analysis failure visible, since the near-positive result depends on excluding a meaningful subset of patients.

Revenue Trajectory and Financial Metrics

PMOs generated US$228.6M in 1Q26 revenue, essentially in line with the Street estimate of US$229M but down 11.8% Q/Q from US$259.2M in 4Q25. The analysts note that traditional approval would support the durability of that revenue stream and reduce business-continuity risk, but they expect approval to carry less positive impact than the potential negative fallout from a Complete Response Letter or additional-data request, because their model already ascribes full value to marketed PMOs. Sarepta cites more than 1,800 amenable patients treated worldwide and RWE signals across ventilation, pulmonary decline, survival, ambulation, cardiac outcomes, and hospitalization, though the analysts maintain these data do not erase the failed primary endpoint.

The next stock-moving event is 2Q26 revenue—particularly whether ELEVIDYS declines again from 1Q26's US$102M and whether PMOs stabilize near the roughly US$230M quarterly run-rate. On the balance sheet, the company holds US$735.1M in cash against US$838.2M in total debt, with a market capitalization of US$1,897M and an enterprise value of US$2,000M. H.C. Wainwright projects full-year 2026 revenue of US$1,744.4M, declining to US$1,286.7M in 2027.

Valuation and Risks

The US$5.00 price target is derived from a 12-month discounted cash flow analysis using a 12% discount rate and a 2% terminal rate of decline, ascribing 100% probability of approval to marketed products. Upside risks include faster-than-expected ELEVIDYS demand recovery, PMO traditional approvals, Cohort 8 data supporting nonambulatory re-entry with payer adoption, a clean sirolimus package enabling SRP-9003 BLA progress, and stronger-than-expected DM1/FSHD functional or biomarker data.

Downside risks include continued ELEVIDYS underutilization, additional safety events, payer pushback in non-ambulatory patients, PMO erosion, or placebo-controlled data that weakens confidence in ELEVIDYS efficacy. Shares closed at US$17.97 on June 30, 2026, leaving roughly 72% potential downside to the US$5.00 target.

Important Disclosures:

This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for H.C. Wainwright & Co., Sarepta Therapeutics Inc., July 1, 2026

This material is confidential and intended for use by Institutional Accounts as defined in FINRA Rule 4512(c). It may also be privileged or otherwise protected by work product immunity or other legal rules. If you have received it by mistake, please let us know by e-mail reply to unsubscribe@hcwresearch.com and delete it from your system; you may not copy this message or disclose its contents to anyone. The integrity and security of this message cannot be guaranteed on the Internet. H.C. WAINWRIGHT & CO, LLC RATING SYSTEM: H.C. Wainwright employs a three tier rating system for evaluating both the potential return and risk associated with owning common equity shares of rated firms. The expected return of any given equity is measured on a RELATIVE basis of other companies in the same sector. The price objective is calculated to estimate the potential movements in price that a given equity could reach provided certain targets are met over a defined time horizon. Price objectives are subject to external factors including industry events and market volatility. RETURN ASSESSMENT Market Outperform (Buy): The common stock of the company is expected to outperform a passive index comprised of all the common stock of companies within the same sector. Market Perform (Neutral): The common stock of the company is expected to mimic the performance of a passive index comprised of all the common stock of companies within the same sector. Market Underperform (Sell): The common stock of the company is expected to underperform a passive index comprised of all the common stock of companies within the same sector. Rating and Price Target History for: Sarepta Therapeutics, Inc. (SRPT-US) as of 06-30-2026 200 150 100 50 0 Q2 Q3 2024 Q1 Q2 Q3 2025 Q1 Q2 Q3 2026 Q1 Q2 D:UR:NA 10/08/20 I:SELL:$80.00 11/25/24 SELL:$75.00 12/02/24 NEUTRAL:$75.00 04/02/25 NEUTRAL:$40.00 05/07/25 SELL:$10.00 06/16/25 SELL:$0.00 07/21/25 SELL:$5.00 07/29/25 Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months. Distribution of Ratings Table as of June 30, 2026 IB Service/Past 12 Months Ratings Count Percent Count Percent Buy 531 83.89% 154 29.00% Neutral 46 7.27% 12 26.09% Sell 2 0.32% 0 0.00% Under Review 54 8.53% 22 40.74% H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer. I, Mitchell S. Kapoor and Raghuram Selvaraju, Ph.D. , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies. None of the research analysts or the research analyst’s household has a financial interest in the securities of Sarepta Therapeutics, Inc. (including, without limitation, any option, right, warrant, future, long or short position). As of May 31, 2026 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Sarepta Therapeutics, Inc.. Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services. The Firm or its affiliates did not receive compensation from Sarepta Therapeutics, Inc. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report. The Firm does not make a market in Sarepta Therapeutics, Inc. as of the date of this research report. The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously. No part of this report may be reproduced in any form without the expressed permission of H.C. Wainwright & Co., LLC. Additional information available upon request. H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report. H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report. H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of this report and are subject to change without notice. Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.

( Companies Mentioned: SRPT:NASDAQ, )

Grey Matters Health Inc. Targets Alzheimer's PET Imaging Opportunity

Tue, 07 Jul 2026 00:00:00 PST

Source: Streetwise Reports 07/07/2026

Grey Matters Health Inc. advances first U.S. brain-dedicated PET clinic for Alzheimer's detection amid surging diagnostics demand. Learn the key facts for investors.

Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) is positioning itself at the center of a rapidly expanding market for Alzheimer's disease diagnostics.

The company recently announced that it has taken delivery of its first brain-dedicated Positron Emission Tomography (PET) scanning system for its flagship NovaScan Neuroimaging Clinics location, which is opening soon in Davie, Florida.

Alzheimer's Diagnostics Market Opportunity

The global Alzheimer's disease diagnostics market is experiencing strong growth driven by new disease-modifying therapies and the need for accurate patient screening. William Blair wrote on May 11 that the Alzheimer's treatment landscape had been rapidly changing following recent regulatory approvals for disease-modifying therapies, creating an urgent need for accurate patient screening and contributing to growth in the global Alzheimer's diagnostics market.

According to a June 15 report from Grand View Research, the global Alzheimer's disease diagnostics market was valued at US$9.2 billion in 2025 and was estimated to reach US$10.2 billion in 2026. Imaging techniques accounted for the largest share of the diagnostics market at 40.8 percent in 2025, while North America represented 47.5 percent of global revenue.

Why Grey Matters Health Stands Out

Grey Matters Health is building the first clinic in the United States dedicated exclusively to brain-only PET scanning for early Alzheimer's detection through beta-amyloid imaging. The clinic will also serve as a diagnostic tool for other neurodegenerative diseases, including frontotemporal dementia, Parkinson's disease, and Lewy body dementia.

The facility will use the U.S. FDA-cleared CareMiBrain PET Brain Scanning System, which does not require an integrated Computed Tomography component. This design delivers 25 percent less radiation exposure and uses a chair-style configuration for patient comfort. Scans for beta-amyloid plaque detection are covered by Medicare, Medicaid, and private insurance for patients aged 65 and older.

Key Investor Takeaways

Grey Matters Health is opening the first U.S. brain-dedicated PET clinic in Davie, Florida, targeting early Alzheimer's detection.
The CareMiBrain system offers lower radiation and insurance reimbursement starting at US$4,500 per scan.
Two FDA-approved monoclonal antibody treatments require positive beta-amyloid scans before use, creating ongoing demand.
Analyst price targets have already been achieved with a current Technical Rating of Strong Speculative Buy.
The clinic is located within a one-hour drive of approximately six million people with low daily break-even volume.
Management and insiders hold about 11 percent, while institutions own roughly 21 percent.

Unique Business Model and Technology Advantage

The company's NovaScan Neuroimaging Clinics model focuses on high-volume, brain-specific PET imaging rather than full-body systems. The CareMiBrain scanner supports both diagnostic and monitoring scans required by new Alzheimer's therapies such as Leqembi from Eisai and Biogen and Kisunla from Eli Lilly. Both treatments are covered by Medicare, Medicaid, and private insurance and require a positive beta-amyloid brain scan or spinal tap prior to initiation, followed by additional PET scans to track patient progress.

Future Market Insights reported on June 16 that precision medicine and biomarker-guided testing had continued reshaping healthcare diagnostics. Accurate biomarker testing is essential as therapies become increasingly targeted.

Industry Timing and Trends

Grand View Research noted that the growing global burden of Alzheimer's has intensified the need for early detection and precise diagnosis. Advances in genomics, proteomics, and metabolomics have expanded the use of biomarkers, while PET imaging continues to play a crucial role. Advances in image analysis and machine learning have improved the accuracy and reliability of neuroimaging.

William Blair described PET imaging as the gold standard for visualizing amyloid plaques. Increased use of amyloid-targeted therapies, together with favorable reimbursement policies, has supported demand for Alzheimer's PET imaging. Blood-based biomarker tests have emerged as cost-effective screening tools that help identify patients requiring more advanced imaging.

Analyst Views and Valuation

¹In a March 26 report, analyst Stewart Thomson discussed Grey Matters Health Inc.'s Alzheimer's disease imaging strategy, highlighting the company's plans to establish a network of specialized neuroimaging clinics in the United States focused on brain-specific Positron Emission Tomography imaging. Thomson wrote that Grey Matters was pursuing a strategy centered on brain-optimized PET scans for the diagnosis of Alzheimer's disease and referenced the company's objective of targeting what it described as a CA$6.9 billion emerging market.

Thomson assigned Grey Matters a Technical Rating: Strong Speculative Buy and set price targets of CA$0.08 in the short term, CA$0.17 in the medium term, and CA$0.40 in the long term. Each of those price targets has since been achieved.

Clinic Opening and Operational Milestones

Grey Matters is continuing preparations for the opening of its first NovaScan Neuroimaging Clinics location in Davie, Florida. Preparations include securing all required licenses, completing construction, and installing technical and operational systems. The company plans to provide an update on the official clinic opening date and the timing for accepting patient referrals.

According to the company's May 2026 investor presentation, the first NovaScan Neuroimaging Clinics location is situated at the HCA Florida University Medical Office Building on the HCA Florida University Hospital campus in Davie, Florida. The location is within a one-hour drive of approximately six million people.

The investor presentation states that the CareMiBrain PET Brain Scanning System will be the first of its kind purchased for operation in the United States. The system is FDA-cleared, does not require a CT scan, provides 25 percent less radiation exposure, and scans are covered by Medicare, Medicaid, and private insurance with a stated minimum reimbursement of US$4,500 per scan.

The presentation further outlines operating metrics for a NovaScan clinic, including a maximum of 15 scans per day, an annual maximum capacity of 3,600 scans, monthly operating costs of US$70,000, and a stated break-even point of 1.6 scans per day. [OWNERSHIP_CHART-9895]

Share Structure and Ownership

²Management and insiders own about 11 percent of the company, and about 21 percent is owned by institutions. The rest is with retail. Top shareholders include Alpha North Asset Management with 20.52 percent, Chief Executive Officer Christopher Moreau with 5.05 percent, Chairman of the Board Harry Bloomfield with 1.97 percent, Chief Financial Officer James Kinley with 1.4 percent, and Director Rajpaul Attariwala with 1.2 percent.

Grey Matters has 54.1 million outstanding shares, a market cap of CA$1.37 million, and a 52-week range of CA$0.035 - CA$0.10.

Common Questions from Investors

What is the CareMiBrain system, and why does it matter? It is an FDA-cleared brain-dedicated PET scanner that requires no CT component, reduces radiation exposure by 25 percent, and qualifies for insurance reimbursement starting at US$4,500 per scan.

Why are new Alzheimer's treatments driving demand for PET scans? Leqembi and Kisunla require a positive beta-amyloid scan before treatment begins and additional scans to monitor progress, creating recurring demand.

What is the break-even volume for a NovaScan clinic? The clinic breaks even at just 1.6 scans per day, while maximum capacity reaches 3,600 scans annually.

Where is the first clinic located? It is located at the HCA Florida University Medical Office Building on the HCA Florida University Hospital campus in Davie, Florida, within reach of six million people.

Has the company achieved analyst price targets? Yes, all three targets set by analyst Stewart Thomson (CA$0.08 short-term, CA$0.17 medium-term, CA$0.40 long-term) have been reached.

Grey Matters Health is executing on a focused strategy to address a clear clinical need with specialized technology and favorable reimbursement. Investors should monitor upcoming updates on the Florida clinic opening and patient referral timelines as key near-term milestones.

[SMNLINSERT]

Important Disclosures:

As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Grey Matters Health.
Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Disclosure for the quote from the Stewart Thomson article published on March 26, 2026

For the quoted article (published on March 26, 2026), Grey Matters Health has paid Street Smart, an affiliate of Streetwise Reports, US$3,000.
Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts. The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: GREY:CSE; AGW0:FRA; AGNPF:OTCQB, )

BioLargo (BLGO) Aligns CEO Pay With Growth as Contracts Renew

Tue, 07 Jul 2026 00:00:00 PST

Source: Streetwise Reports 07/07/2026

BioLargo Inc. (BLGO) secures $1.4M Air Force contract renewals while advancing PFAS and wound care technologies through key partnerships and aligned leadership incentives.

Cleantech and life sciences innovator BioLargo Inc. (BLGO:OTCQX) is positioning itself at the intersection of recurring government services and high-growth environmental and medical markets. Recent contract renewals provide a stable revenue foundation while the company advances specialized technologies targeting PFAS contamination and advanced wound care.

The global PFAS treatment market offers substantial opportunities for companies with proven removal and destruction capabilities. Valued at US$2.8 billion in 2025, the sector is projected to reach US$4.8 billion by 2033, reflecting a 7.1% compound annual growth rate, according to Grand View Research. North America currently accounts for 41.9% of revenue due to strict regulations and elevated water-quality standards. Parallel expansion is occurring in the anti-biofilm wound dressing market, forecast to grow at a 9.8% CAGR from 2025 to 2035 and reach US$2.4 billion.

Why BioLargo Stands Out for Retail Investors

BioLargo operates through distinct subsidiaries that address separate high-potential end markets while sharing engineering and commercialization expertise. This diversified model reduces single-product risk and creates multiple pathways to revenue.

The engineering division, BioLargo Engineering, Science & Technologies (BLEST), recently renewed contracts valued at over US$1.4 million spanning twelve months. These agreements continue air quality and environmental compliance work at five U.S. Air Force bases, according to a July 1 release. Services include regulatory compliance, permitting, testing, data management, and inventory tracking.

Leadership Alignment and Capital Structure

CEO Dennis P. Calvert accepted equity in place of cash compensation, receiving 699,569 shares on June 30, 2026, and an additional 219,914 shares on July 1, 2026. The shares, valued near US$0.1135 and US$0.113, respectively, are subject to a lock-up that prevents sale until the company achieves US$40 million in consolidated gross revenue, a US$300 million market capitalization, or a change of control. This structure directly ties executive reward to long-term milestones that benefit all shareholders.

Key Investor Takeaways

Recurring engineering revenue from U.S. Air Force contracts provides a predictable base alongside larger project work and product sales.
CEO equity compensation with a strict performance-based lock-up aligns management incentives with retail investor outcomes.
PFAS treatment market growth at 7.1% CAGR through 2033 creates a favorable backdrop for BioLargo's Aqueous Electrostatic Concentrator technology.
Exclusive distribution agreement for ViaCLYR wound irrigation solution expands geographic reach into Gulf Cooperation Council and North African markets.
Analyst coverage maintains Buy and Speculative Buy ratings, citing diversified subsidiary model and multiple commercialization catalysts.
Market capitalization of approximately US$35.62 million offers leverage to successful execution across environmental and medical platforms.

Strategic Partnerships Accelerating Commercialization

In May, BioLargo announced that BioLargo Equipment Solutions & Technologies Inc. (BEST) signed a memorandum of understanding with Aquatech to combine the Aqueous Electrostatic Concentrator PFAS collection technology with Aquatech's destruction systems. The non-exclusive framework targets industrial, municipal, and government clients seeking complete PFAS management solutions. Aquatech was named Water Technology Company of the Year at the 2025 Global Water Awards.

Also in May, Clyra Medical Technologies Inc. entered an exclusive distribution agreement with Al-Hikma FZCO.

In the same month, Clyra Medical Technologies Inc. announced the commercialization of ViaCLYR wound irrigation solution across the Gulf Cooperation Council, Levant, and North Africa. ViaCLYR utilizes Clyrasept Copper-Iodine Complex Solution and holds FDA 510(k) clearance for acute and chronic wounds with up to 72 hours of sustained antimicrobial activity.

Analyst Perspectives on Technology Portfolio

¹Technical Analyst John Newell highlighted BioLargo's progress in infection control and wound care in a review of the stock on March 11, noting the company's systematic approach to scientific validation and partnership development. Newell rated the shares a Speculative Buy.

Oak Ridge Financial Analyst Richard Ryan maintained a Buy rating, describing the business model as a hub-and-spoke format that prototypes technologies, then partners for commercialization while retaining meaningful ownership in each segment.

BioLargo is also advancing the Cellinity long-duration battery platform, which uses earth-abundant materials to address grid-scale energy storage limitations of conventional lithium-ion systems. The company intends to license the technology and collaborate with manufacturing partners.

Market Timing and Growth Drivers

PFAS regulatory pressure continues to intensify across North America, Europe, and the Asia Pacific, prompting utilities and industries to invest in removal and destruction solutions.

A recent study by Future Market Insights forecasts similar momentum in wound care, driven by rising surgical site infections, diabetic ulcers, and chronic wounds that require advanced biofilm-resistant dressings. BioLargo's portfolio addresses both trends through separate subsidiaries. [OWNERSHIP_CHART-6976]

Ownership and Share Structure

²Insiders and management hold approximately 13.62% of BioLargo. Institutions with 13F-disclosed holdings own 0.04%, while retail investors account for the remaining 86.34%.

The company has a market capitalization of US$35.62 million, 320.88 million shares outstanding, and 276.31 million shares in the float. Shares have traded between US$0.10 and US$0.23 over the past 52 weeks.

Common Questions from Investors

Q: What do the renewed Air Force contracts mean for revenue stability?
A: The US$1.4 million renewals extend multi-year work at five bases for another twelve months, providing repeatable engineering revenue while the company pursues larger projects and product commercialization.

Q: How does the CEO's equity arrangement affect shareholders?
A: Shares received in lieu of cash are locked until the company reaches US$40 million in gross revenue or US$300 million market cap, directly aligning executive outcomes with long-term value creation.

Q: What is the significance of the Aquatech MOU?
A: The agreement combines BioLargo's PFAS concentrator technology with Aquatech's destruction systems, creating integrated solutions for a rapidly expanding, regulatory-driven market.

Q: Where is ViaCLYR currently approved for sale?
A: ViaCLYR holds FDA 510(k) clearance in the United States and is now covered by an exclusive distribution agreement spanning the Gulf Cooperation Council, Levant, and North Africa.

Q: What markets does BioLargo target beyond PFAS and wound care?
A: The company is also developing a long-duration energy storage battery using earth-abundant materials for potential licensing to grid-scale applications.

BioLargo's combination of recurring government contracts, performance-aligned leadership, and exposure to expanding PFAS and wound care markets provides retail investors with multiple near-term catalysts within a modest market capitalization. Execution on partnerships and technology validation will determine the pace of value realization across its diversified platform.

Important Disclosures:

BioLargo Inc. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$3,000 and US$6,000.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of BioLargo Inc.
Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosure for the quote from the John Newell article published on March 11, 2026

For the quoted article (published on March 11, 2026), BioLargo has paid Street Smart, an affiliate of Streetwise Reports, US$2,550.
Author Certification and Compensation: [John Newell of John Newell and Associates] was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Newell holds a Chartered Investment Management (CIM) designation (2015) and a U.S. Portfolio Manager designation (2015). The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

John Newell Disclaimer

As always it is important to note that investing in precious metals like silver carries risks, and market conditions can change violently with shock and awe tactics, that we have seen over the past 20 years. Before making any investment decisions, it's advisable consult with a financial advisor if needed. Also the practice of conducting thorough research and to consider your investment goals and risk tolerance.

Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: BLGO:OTCQX, )

Digital Health Platform Lands Access to Hundreds of Thousands of Covered Lives

Wed, 08 Jul 2026 00:00:00 PST

Source: Streetwise Reports 07/08/2026

DarioHealth Corp. (DRIO:NASDAQ) signed a new agreement through its Amwell partnership that makes its cardiometabolic platform available to a major Arizona health insurer's ASO business, representing hundreds of thousands of covered lives.

DarioHealth Corp. (DRIO:NASDAQ) announced a new agreement with a major health insurer with a stronghold in Arizona through its strategic channel partnership with Amwell. According to the company, the agreement makes Dario's cardiometabolic solution available to the insurer's Administrative Services Only (ASO) book of business, representing access to hundreds of thousands of covered lives.

The company said its cardiometabolic solution will be positioned within the insurer's ASO portfolio for employer clients seeking to address diabetes, hypertension, and weight management through a unified, behaviorally driven approach. Employers will be able to adopt the solution based on their specific population needs and benefits strategy, with tailored deployments at scale.

"This agreement demonstrates how our channel strategy is driving scalable, efficient access to large employer populations," Dario Chief Executive Officer Erez Raphael said in a company news release. "By leveraging channel partner infrastructure and relationships, we can rapidly reach a high-value ASO population like this and embed Dario within the health plan ecosystem."

According to the company, Dario's solution delivers up to five times return on investment to employers, as demonstrated in a study funded by Sanofi and supported by more than 100 scientific studies, including peer-reviewed journal publications and conference abstracts. The company said savings for clients are generated through fewer hospitalizations and improvements in metrics, including systolic blood pressure, A1C, and hyperglycemic events.

Dario also said its partnership with Amwell supports its capital-efficient growth model by lowering customer acquisition costs, accelerating sales cycles, and supporting expansion across employer populations. According to the company, it has access to more than 116 million covered lives through its expanding channel partnership network.

Chronic Care Drives Digital Health Adoption

According to a May report from Grand View Research, the global digital health market was valued at US$347.4 billion in 2025 and was estimated to reach US$420.2 billion in 2026. The report stated that North America accounted for 37.1% of global revenue in 2025, supported by "a strong domestic digital health market for telehealthcare platform developers, mHealth app providers, wearable device manufacturers, and e-prescription systems."

Grand View Research wrote that "the rising incidence of chronic conditions such as diabetes, heart disease, and cancer is fueling the demand for remote monitoring and management solutions." The report added that digital health tools helped patients "track their health, adhere to treatment plans, and communicate more effectively with healthcare providers." It also noted that diabetes represented the largest application segment in the digital health market, accounting for more than 25% of market share in 2025. The report added that telehealth held the largest technology segment with a 44.7% market share, supported by increasing adoption among patients and healthcare providers.

Writing on July 6, Market.us Media reported that the global home healthcare market was valued at US$420.8 billion in 2024 and was projected to reach approximately US$900.1 billion by 2034, reflecting a 7.9% compound annual growth rate. The report stated that advances in digital health technologies, including "remote patient monitoring and telehealth, have further enhanced the quality and accessibility of home-based care by enabling continuous communication between patients and healthcare professionals."

Market.us Media also noted that North America held more than 40.2% of the global home healthcare market in 2024. According to the report, "the rising prevalence of chronic diseases, including cardiovascular disorders, diabetes, and respiratory conditions, along with a growing aging population, has significantly increased the need for personalized healthcare delivered at home." It added that wearable health devices, AI-enabled telemedicine platforms, connected monitoring solutions and remote patient monitoring were expanding the availability of home-based care while supporting chronic disease management and reducing unnecessary hospital visits.

Analyst Perspective: Commercial Execution and Platform Expansion Remained the Focus

In a July 5 weekly digital health report, David M. Grossman of Stifel wrote that the Stifel Digital Health Index gained 11% during the week, outperforming the Bloomberg 2000 Growth Index, which was flat. The firm noted that the digital health index had outperformed the broader growth benchmark by 3,700 basis points over the previous 90 days, rising 56% compared with 19%.

Stifel stated that trading activity during the holiday-shortened week was "largely driven by sentiment surrounding AI announcements (+/-), rotation out of semiconductors (+), and company-specific news (+/-)." The firm also reported that valuation multiples across several digital health segments had increased over the previous 90 days, with the Virtual Care and Remote Patient Monitoring group trading at 2.4x next-12-month enterprise value-to-revenue as of July 2, compared with 1.5x 90 days earlier.

The report also highlighted broader industry developments centered on artificial intelligence and digital health adoption. Stifel cited an industry survey that found "roughly three in ten adults self-reported turning to social media (31%) or AI chatbots (29%) at least monthly for health information and advice." Among AI users, the most common reason was "wanting quick or immediate advice (65%)," while many also reported using AI before deciding whether to see a healthcare provider.

Within the report, Stifel highlighted DarioHealth's recent announcements, including an expanded relationship with a national health plan and a strategic collaboration with Beluga Health. The firm also noted Dario's appointment of former Humana Chief Compliance Officer Sean O'Reilly to its advisory board and maintained a Buy rating with a US$7.28 price target.

Earlier research from CG Capital also maintained an "Outperform" rating and US$28.00 price target on DarioHealth. In its May 12 report, the firm highlighted sequential revenue growth, operating expense discipline, commercial pipeline expansion and implementation of enterprise client wins. CG Capital also wrote that the company's platform had "consolidated four formerly separate digital health businesses (diabetes, hypertension, MSK, behavioral health) onto a single technology and commercial chassis under the DarioIQ AI architecture" and that it "now addresses 6+ chronic conditions across a single member experience with 100+ peer-reviewed studies." [OWNERSHIP_CHART-9981]

Following first-quarter results, CG Capital reiterated its "Outperform" rating and US$28.00 price target in a May 13 update. The firm cited a second consecutive quarter of sequential revenue growth, lower operating expenses, continued expansion of the commercial pipeline, new customer additions and approximately US$13 million in contracted and late-stage business progressing through implementation. CG Capital also pointed to early DarioIQ results showing up to a 40% improvement in member retention and up to a 57% increase in active sessions compared with a control group.

Channel Expansion and Multi-Condition Strategy

According to the company's May 2026 corporate presentation, Dario's commercial strategy includes working across employers, health plans, and channel partners. The presentation states that the company intends to continue leveraging broker and consultant relationships, expand engagement with health plans, including pharmacy benefit managers and third-party administrators, and continue working with delivery partners while evaluating additional channel partnerships.

The presentation also outlines initiatives to expand product reach by adding conditions to increase eligible populations and covered lives, improving technology to increase enrollment rates, and adding new condition partners. It further describes efforts to improve enrollment and engagement through technology enhancements and the addition of claims-based data and analytics.

Ownership and Share Information¹

DarioHealth Corp. has a market cap of US$51.41 million, with 7.3 million shares outstanding.

The company's 52-week range is US$5.84-US$17.74.

Institutions own 39.4% of shares, while Strategic Investors own 7.5%.

Management & Insiders own 4.5% of shares, and the remaining 48.6% of shares are held by Retail.

Important Disclosures:

DarioHealth Corp. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$3,000 and US$6,000.
James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: DRIO:NASDAQ, )

First-of-Its-Kind US Brain Imaging Clinic Takes Delivery of Key PET Scanner

Tue, 07 Jul 2026 00:00:00 PST

Source: Streetwise Reports 07/07/2026

Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) received its first brain-dedicated PET scanning system for its flagship Florida NovaScan Neuroimaging Clinic, which the company said will be the first U.S. facility dedicated to brain-only PET imaging for Alzheimer's disease and other neurological conditions.

Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) announced that it has taken delivery of its first brain-dedicated Positron Emission Tomography (PET) scanning system for its flagship NovaScan Neuroimaging Clinics location, which is opening soon in Davie, Florida.

According to the company, the clinic will be the first of its kind in the United States to offer brain-only PET scanning to assist in meeting demand for early Alzheimer's disease detection through beta-amyloid imaging. The company said the facility will also provide a diagnostic imaging tool for other neurodegenerative diseases.

The clinic will feature the U.S. FDA-cleared CareMiBrain PET Brain Scanning System, which does not require an integrated Computed Tomography (CT) component to produce diagnostic images. Grey Matters said the system results in 25% less radiation exposure for patients and features a chair-style design. The company added that brain PET scans for beta-amyloid plaque detection associated with advancing Alzheimer's disease are covered by Medicare, Medicaid, and private insurance for patients aged 65 and older.

"Taking delivery of our first brain-dedicated PET scanner is a tremendous milestone for the company," Christopher J. Moreau, CEO of Grey Matters Health, said in a company news release. "We look forward to launching our flagship location in Florida, which will be the first of many neuroimaging clinics we plan to open across the U.S., featuring this revolutionary new technology."

The inaugural clinic will be located at the HCA Florida University Medical Office Building on the HCA Florida University Hospital campus. Grey Matters said it will be the first clinic in the United States to provide brain-dedicated PET scans to aid the medical community in the diagnosis of Alzheimer's disease.

In addition to beta-amyloid imaging, the CareMiBrain system will be used for imaging related to frontotemporal dementia, Parkinson's disease, Lewy body dementia, and select neuro-oncology applications.

The company also stated that the U.S. FDA has approved two monoclonal antibody treatments for Alzheimer's disease, Leqembi from Eisai and Biogen, and Kisunla from Eli Lilly, which are covered by Medicare, Medicaid, and private insurance. According to Grey Matters, both treatments require a positive beta-amyloid brain scan or spinal tap before patients can receive them, and patients receiving treatment also require additional brain PET scans to monitor their progress.

Alzheimer's Diagnostics Market Continues to Evolve

William Blair wrote on May 11 that "the Alzheimer's treatment landscape" had been "rapidly changing following recent regulatory approvals for disease-modifying therapies," creating "an urgent need for accurate patient screening" and contributing to growth in the global Alzheimer's diagnostics market. The firm stated that patients had first needed to be confirmed as having amyloid-beta pathology before treatment could begin, making diagnostics "a critical gatekeeper." It also noted that treatment guidelines had recommended continued monitoring during therapy, creating "ongoing demand for diagnostic testing throughout a patient's care journey."

William Blair also described PET imaging as "the gold standard for visualizing amyloid plaques" and stated that increased use of amyloid-targeted therapies, together with favorable reimbursement and coverage policies, had supported demand for Alzheimer's PET imaging. The firm added that blood-based biomarker tests had emerged as cost-effective screening tools that helped identify patients requiring more advanced imaging, stating that "these diagnostic workflows create a harmonious system that ensures consistent demand across both advanced and accessible testing modalities."

According to a June 15 report from Grand View Research, the global Alzheimer's disease diagnostics market was valued at US$9.2 billion in 2025 and was estimated to reach US$10.2 billion in 2026. The firm stated that "increasing prevalence of Alzheimer's Disease (AD), growing use of biomarkers in disease diagnostics, growing adoption of personalized products, and increasing technological advancements in medical imaging" had been among the factors supporting demand for Alzheimer's diagnostics. Grand View Research also reported that imaging techniques accounted for the largest share of the diagnostics market at 40.8% in 2025, while North America represented 47.5% of global revenue.

Grand View Research also wrote that "the growing global burden of Alzheimer's has intensified the need for early detection and precise diagnosis." The report stated that advances in genomics, proteomics, and metabolomics had expanded the use of biomarkers, while positron emission tomography (PET) imaging had continued to play "a crucial role in Alzheimer's diagnosis." It added that advances in image analysis and machine learning had improved the accuracy and reliability of neuroimaging, allowing diagnostic approaches to evolve "from traditional cognitive assessments to advanced neuroimaging and CSF assays."

The report further noted that the Alzheimer's disease diagnostics market had been "characterized by a high degree of innovation," driven by advances in biomarkers and neuroimaging technologies that enabled earlier and more accurate diagnosis. It also stated that the imaging technique segment continued to lead the market because of "the critical need for early and accurate disease detection," with technologies including CT, PET, and functional MRI serving as essential tools for diagnosing and monitoring Alzheimer's disease.

Future Market Insights reported on June 16 that precision medicine and biomarker-guided testing had continued reshaping healthcare diagnostics. The firm wrote that "accurate biomarker testing is essential" as therapies became increasingly targeted and stated that advances in digital pathology, automation, and AI-enabled diagnostics had reduced turnaround times while improving diagnostic consistency. It also reported that hospitals and diagnostic laboratories had continued expanding molecular testing capabilities as biomarker-driven diagnostics became more integrated into routine clinical workflows. [OWNERSHIP_CHART-9895]

Analyst Commentary on Alzheimer's Disease Imaging

Thomson wrote that Grey Matters was pursuing a strategy centered on brain-optimized PET scans for the diagnosis of Alzheimer's disease. He also referenced the company's objective of targeting what it described as a CA$6.9 billion emerging market through the use of dedicated brain-specific PET imaging technology.

According to Thomson, the company planned to develop neuroimaging clinics dedicated to Alzheimer's disease detection using FDA-cleared brain-specific PET scanning systems designed for early-stage diagnosis.

Thomson assigned Grey Matters a "Technical Rating: Strong Speculative Buy" and set price targets of CA$0.08 in the short term, CA$0.17 in the medium term, and CA$0.40 in the long term. According to the report, each of those price targets has since been achieved.

Clinic Opening and Operational Milestones

Grey Matters said it is continuing preparations for the opening of its first NovaScan Neuroimaging Clinics location in Davie, Florida. Those preparations include securing all required licenses, completing construction work, and installing all technical and operational systems.

The company said it plans to provide an update on the official clinic opening date and the timing for accepting patient referrals.

According to the company's May 2026 investor presentation, the first NovaScan Neuroimaging Clinics location is situated at the HCA Florida University Medical Office Building on the HCA Florida University Hospital campus in Davie, Florida. The presentation states the location is within a one-hour drive of approximately six million people.

The investor presentation also states that the CareMiBrain PET Brain Scanning System will be the first of its kind purchased for operation in the United States. The system is FDA-cleared, does not require a CT scan, provides 25% less radiation exposure, and scans are covered by Medicare, Medicaid, and private insurance, with a stated minimum reimbursement of US$4,500 per scan.

Ownership and Share Structure²

Management and insiders own about 11% of the company, and about 21% is owned by institutions. The rest is with retail.

Top shareholders include Alpha North Asset Management with 20.52%, Chief Executive Officer Christopher Moreau with 5.05%, Chairman of the Board Harry Bloomfield with 1.97%, Chief Financial Officer James Kinley with 1.4%, and Director Rajpaul Attariwala with 1.2%.

Grey Matters has 54.1 million outstanding shares, a market cap of CA$1.37 million, and a 52-week range of CA$0.035 - CA$0.10.

Important Disclosures:

As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Grey Matters Health.
James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Disclosure for the quote from the Stewart Thomson article published on March 26, 2026

For the quoted article (published on March 26, 2026), Grey Matters Health has paid Street Smart, an affiliate of Streetwise Reports, US$3,000.
Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts. The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: GREY:CSE; AGW0:FRA; AGNPF:OTCQB, )

Bullish Charts and Commercial Breakthroughs For Florida Biomanufacturer Could Fuel Upwards Valuation

Tue, 14 Jul 2026 00:00:00 PST

Source: Stewart Thomson 07/14/2026

Technical Analyst Stewart Thomson takes a look at Dyadic International Inc. (DYAI:NASDAQ) as it secures strategic partnerships in the human and animal health, food technology, cell culture media, and industrial enzyme sectors.

Dyadic International Inc. (DYAI:NASDAQ) is a U.S. biotechnology company specializing in protein expression and manufacturing solutions, leveraging its proprietary C1 and Dapibus fungus platforms.

Dyadic has secured strategic partnerships in the human and animal health, food technology, cell culture media, and industrial enzyme sectors.

A combination of new contract wins, platform scalability, and a broad market rotation into small-cap biotech stocks is creating the potential for positive cash flow and higher valuation.

As of July 2026, the company appears to have successfully transitioned from a pure R&D start-up to a commercial biomanufacturer.

Biotech: A Bullish Market Sector

Technical analysis shows biotech to be one of the hottest market sectors, and the charts suggest it could stay hot for a long time. Pullbacks can be bought. In a nutshell, institutional and retail investors both want to invest in market leaders, and this sector is one of the strongest.

Figure 1: XBI:NYSE Biotech Sector ETF Chart

Technical Analysis and Observations:

Biotechnology is in a major bull trend.
OBV (On Balance Volume) is confirming the underlying strength of the trend.

Figure 2: XBI Versus SP500 Index Comparison Chart

Technical Analysis & Observations:

This chart clearly shows biotech is outperforming the S&P 500 index.
Institutional investors are generally attracted to sectors exhibiting relative strength.

Commercial Momentum and Platform Validation

The U.S. government's significant shift away from foreign-dependent mRNA supply chains has created specific demand for non-mRNA, protein-based platforms like Dyadic's C1.

The primary fundamental driver for Dyadic's potential upside valuation re-rating is the successful commercial deployment of this C1 platform. Unlike traditional mammalian or bacterial systems, the C1 fungus offers rapid development, scale-up, higher yields, and lower production costs, which is a critical advantage in the current economic climate.

Strategic Expansion with Solid Partnerships

The company has moved beyond pilot programs into multi-year supply agreements. Recent announcements are validating the platform's ability to produce complex biologics at commercial scale.

For example, on March 2, 2026, Dyadic announced the planned 2026 commercialization of recombinant non-animal bovine chymosin enzyme with Denmark-based Inzymes. The company received a US$200,000 milestone payment for completing development, moving the project into a commercial phase that targets the multi-billion-dollar dairy enzyme market.

National Security

Dyadic's C1 platform is viewed as a strategic reserve technology.

It's stable, does not require ultra-cold chains, and can be produced entirely within the U.S.

Investor Risks

Cash Burn: With approximately US$6.6 million in cash and a quarterly burn rate that appears to be near US$2 million, the company may have a clear “runway” only into Q2 2027.
Customer Concentration: Revenue remains heavily dependent on a small number of strategic partners (e.g., Proliant Health & Biologics, Inzymes, Fermbox, and IBT Bioservices).
Lack of Professional Advice: Before taking action with any investment, investors should consult with properly licensed, experienced, and qualified investment advisors and get numerous opinions. Failure to do so increases risk.

Note: The above is not a complete list of risks. Read Dyadic's 10K filing carefully for more information on investment risks. [OWNERSHIP_CHART-4472]

Ownership Breakdown

¹There are about 40 institutional investors holding about 15% of the stock. Strategic entities hold another 25%.

The largest shareholder is the company's founder and CEO, Marc Emalfarb, with about 13% of the stock.

Shares Outstanding

Approximately 36.44 million shares.

Analyst Buy Recommendation

US$5.00 Price Target

On May 14, 2026, Craig-Hallum analysts Matthew Hewitt and Tollef Kohrman said in their research report that they are reiterating their buy recommendation, with a US$5.00 price target for the stock.

They elaborate, “We continue to believe the company's commercialization efforts are bearing fruit as it moves from early-stage development toward initial revenue generation, supported by a growing base of partnerships, distribution agreements, and product launches.”

Undervalued Relative to Peers

Figure 3: Dyadic Versus XBI Ratio Chart

Technical Analysis & Observations:

A potential base pattern has formed for Dyadic against the powerful XBI biotech ETF.
The stock looks ready to stage a significant rally against the XBI.
MACD and RSI are exhibiting bullish leadership. In these types of technical situations, the price tends to follow the indicators and move higher.
Dyadic has some well-known institutional shareholders, including Vanguard. If the company executes on its strategy, it could be picked up by a biotech ETF, and that would automatically bring investment from more institutional investors.

Figure 4: Dyadic Daily Chart

Technical Analysis and Observations:

A double bottom pattern is in play, targeting the US$1.30 zone.
A move to the target area would help secure the company's listing on the Nasdaq, where a lot of biotech stocks trade.
Stochastics and MACD are in rising mode, and the FORCE money flow indicator just flashed a buy signal.

Figure 5: Dyadic Weekly Chart

Technical Analysis and Observations:

A significant bull wedge pattern has formed.
A rally to the US$2.60 area highs appears likely.
OBV (On Balance Volume) is rising aggressively.
Stochastics is on a crossover buy signal, as is MACD.

Investment Thesis Summary

Biotech is a bullish sector, strongly outperforming the SP500 index and getting a lot of institutional investor attention.
Bullish chart action (including a large weekly chart bull wedge; see below) could be attributed to the company's successful deployment of its C1 platform.
The platform could get a major boost from the US government's pivot towards non-mRNA, fungal-based platforms.
With solid partnerships in place and fixed costs appearing to be largely established, new revenue streams should flow directly to the bottom line, which could lead to a substantial improvement in EBITDA margins in late 2026 and 2027.

Stock price at time of writing (July 13, 2026): US$1.00

Short-Term Price Target: US$1.30

Medium-Term Technical Price Target: US$1.90

Long-Term Technical Price Target: US$2.60

Technical Rating: Speculative Buy

Important Disclosures:

For this article, Dyadic International Inc. has paid Street Smart, an affiliate of Streetwise Reports, US$4,000.
Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts. The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.
Statements and opinions expressed are the opinions of the author and not of Streetwise Reports, Street Smart, or their officers. The author is wholly responsible for the accuracy of the statements. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Any disclosures from the author can be found below. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services, or securities of any company.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: DYAI:NASDAQ, )

French Clinical-Stage Biotech's UC Drug Faces 'Best in Disease' Doubts as Analyst Lifts Target Ahead of 4Q26 FDA Filing

Mon, 06 Jul 2026 00:00:00 PST

Source: David Nierengarten 07/06/2026

A Wedbush analyst raised its target on a French biopharma's ulcerative colitis candidate but disputed bullish efficacy claims, flagging Jak competition and a 2027 Crohn's readout.

On July 6, 2026, David Nierengarten, Ph.D., Martin Fan, Ph.D., and Dennis Pak of Wedbush Securities reiterated a NEUTRAL rating and raised their 12-month price target to US$140.00 (from US$110.00) on Abivax SA (ABVX:NASDAQ), implying roughly 3.2% downside from the July 2, 2026 closing price of US$144.65, because the analysts believe the stock's rebound to pre-Phase 3 maintenance-data levels already reflects a "perfection" scenario for lead candidate obefazimod while overstating bullish claims about its competitive profile.

Rebound and the Safety Debate

Wedbush attributes much of the share-price recovery to investor relief that malignancies reported at the most efficacious 50 mg dose were "merely" in line with the rates that produced black box warnings for the Jak inhibitor class, including market leader Rinvoq (from AbbVie Inc., NYSE: ABBV).

The analysts argue two ideas can hold simultaneously: obefazimod 50 mg dosing carries malignancy rates equivalent to the black-boxed Jak class, yet, as evidenced by Jak-class sales in IBD, malignancies at that level are no great inhibitor of sales. They view the ultimate label as a discussion for roughly 1.5 years out.

Disputing the 'Best in Disease' Thesis

The report pushes back directly on the bull refrain that the Phase 3 results are "best in disease," stating flatly that this claim "is not true." While obefazimod showed statistically significant induction in heavily pre-treated patients, Wedbush contends that, absent an active comparator in that post-Jak setting, the achievement is "akin to being the world's loudest whisper." The analysts favor comparing patients with inadequate response to a biologic who have not yet received a Jak inhibitor.

In that framing, obefazimod delivered placebo-adjusted clinical remission of 11.4% among ATIR patients excluding Jak inhibitors (ECCO 2026) — about half of Rinvoq's 22.2% benefit in its most-refractory subgroups (Vermiere et al., 2023, consistent with the FDA label range of 17–28%).

Obefazimod's overall induction of roughly 16% in the ABTECT studies sits notably below Rinvoq, though maintenance data are more comparable (obefazimod 39–40% versus a 34–42% Rinvoq label range in biologic failures). The conclusion: Obefazimod is not the best for the disease.

Commercial and Competitive Outlook

Because patients who fail induction are unlikely to continue therapy, Wedbush expects obefazimod to treat roughly two-thirds of the patients Rinvoq would treat over one year with similar starting cohorts. The analysts agree that obefazimod could be used in the post-Jak setting, but disagree that it will displace the Jaks and their extensive real-world experience. They flag Rinvoq's generic entry in April 2037 as nearly as dangerous to obefazimod's position as its own patent expires in 2039, and model declining obefazimod sales once Rinvoq loses exclusivity.

M&A Prospect?

Wedbush sees a diminishing case for a bid within the next ~12 months.

Valuation and estimates

The revised price target derives from a sum-of-parts DCF of 2027–39E worldwide net income from obefazimod in ulcerative colitis and Crohn's disease, discounted back at 11%, with full credit given to Crohn's despite its earlier stage. Wedbush characterizes the US$140 figure as a "perfection" valuation that requires sales to eventually approach IBD market leader Entyvio (from Takeda Pharmaceutical Company Limited, NYSE: TAK; Tokyo: 4502), adding "we are not worried ABVX will reach it." The changes to the model stem from incorporating recent financing. The firm now models a full-year 2026E GAAP loss of €3.10 per share and a 2027E loss of €3.68 per share, against a market cap near US$10.9 billion, cash of US$7.28 per share, and a 52-week range of US$7.65–US$148.83.

Milestones and risks

Upcoming catalysts include a 4Q26 FDA NDA submission for obefazimod in UC, an IBD combination-therapy candidate selection by year-end 2026, and mid-2027 topline data from the Phase 2 ENHANCE-CD study in Crohn's disease. Key risks cited are clinical and regulatory failure of obefazimod, an inability to achieve sales estimates, potential safety signals, commercial competition, and drug manufacturing or shipment challenges. Wedbush also notes that an acquisition could yield a price sharply higher than its target.

Important Disclosures:

This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for Wedbush, Abivax SA, July 6, 2026

Valuation Sum-of-parts: a DCF valuation of 2027-39E ww net income derived from obefazimod in UC and CD (discounted back by 11%) Company Description ABVX is a clinical-stage biopharmaceutical company developing treatments for inflammatory and immune-mediated diseases (I&I). Lead program obefazimod is a first-in-class enhancer of a microRNA sequence, miR-124. Wedbush Best Ideas List The Wedbush Equity Research Department is focused on delivering alpha within the Life Sciences and TMT verticals. The Best Ideas List comprises our highest rated equities, chosen by our analysts, and vetted by our Investment Committee. To manage risk and avoid thesis creep, we employ an automatic sale rule should a stock move -25% on a relative basis (versus the average move of the S&P 500 and the Russell 2000). Past performance is not an indicator of future results. Actual performance may differ from the performance information contained herein. The prices and performance information are based on data from statistical services, reports, or other sources which WS believes are reliable, but its accuracy cannot be guaranteed. Results presented in this report neither reflect inclusion of dividends nor deductions for commissions, costs, fees, or expenses. Such commissions, costs, fees, or expenses will reduce the actual returns. The volatility of the S&P 500 and/or any other benchmark index presented is materially different from that of the model portfolio and is used to illustrate the general market condition on the results portrayed. Benchmark Indices are unmanaged and cannot be invested in directly. Risks to the Attainment of Our Price Target and Rating: Risks to the attainment of our price target and rating for ABVX include clinical and regulatory failure of obefazimod in target indications, and an inability to achieve sales estimates. The company's lead programs may not prove to be efficacious, or safety signals could halt development. Obefazimod could face commercial challenges from current and future therapies, and logistical challenges in drug manufacturing or shipment could arise. An acquisition could also yield a price sharply higher than our target. Analyst Certification We, David Nierengarten, Martin Fan and Dennis Pak, certify that the views expressed in this report accurately reflect our personal opinions and that we have not and will not, directly or indirectly, receive compensation or other payments in connection with our specific recommendations or views contained in this report. Mentioned Companies Company Rating Price Target Abivax S.A. NEUTRAL €144.65 €140.00 Investment Rating System: OUTPERFORM: Expect the total return of the stock to outperform relative to the median total return of the analyst's (or the analyst's team) coverage universe over the next 6-12 months. NEUTRAL: Expect the total return of the stock to perform in-line with the median total return of the analyst's (or the analyst's team) coverage universe over the next 6-12 months. UNDERPERFORM: Expect the total return of the stock to underperform relative to the median total return of the analyst's (or the analyst's team) coverage universe of the next 6-12 months. The Investment Ratings are based on the expected performance of a stock (based on anticipated total return to price target) relative to the other stocks in the analyst's coverage universe (or the analyst's team coverage).* Rating distribution (as of July 6, 2026) Investment Banking Relationships (as of July 6, 2026) OUTPERFORM: 76.10% OUTPERFORM: 13.61% NEUTRAL: 21.91% NEUTRAL: 9.09% UNDERPERFORM: 1.99% UNDERPERFORM: 0.00%

The Distribution of Ratings is required by FINRA rules; however, WS' stock ratings of Outperform, Neutral, and Underperform most closely conform to Buy, Hold, and Sell, respectively. Please note, however, the definitions are not the same as WS' stock ratings are on a relative basis. The analysts responsible for preparing research reports do not receive compensation based on specific investment banking activity. The analysts receive compensation that is based upon various factors including WS' total revenues, a portion of which are generated by WS' investment banking activities. Company Specific Disclosures This information is subject to change at any time. This research is provided for educational and informational purposes only and is not intended to be relied upon as a forecast, research, or investment advice, and is not a recommendation, offer, or solicitation to buy or sell any securities or to adopt any investment strategy. Investing involves risk, including the risk of loss of principal. Your investments may decline in value due to both real and perceived general market, economic, and industry conditions. Diversification does not ensure profits or protect against loss. This research was prepared without regard to specific investment objectives, strategies, tax status, investment horizon, financial situation or needs of any investor. Wedbush Securities, Inc. (“WSI”) encourages recipients of this report to read all relevant offering documents (e.g., prospectus) pertaining to any investment concerned, including without limitation, information relevant to its investment objectives, risks, and costs before making an investment decision and when deemed necessary, to seek the advice of a legal, tax, and/or accounting professional. Past performance is no guarantee of future results. Reliance upon information in this research is at the sole discretion of the reader. All information in this research is believed to be reliable as of the date on which this research was issued and has been obtained from public sources believed to be reliable. No representation or warranty, either express or implied, is provided in relation to the accuracy or completeness of the information contained herein. The opinions expressed are as of the date written and are subject to change without notice. In addition, this research may contain certain statements deemed to be “forward-looking” statements. All statements, other than historical facts, contained within this document that address activities, events or developments that this research report expects, believes, or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions and analyses made by WSI in light of its experience and perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. Such statements are subject to assumptions, risks, uncertainties, many of which are beyond WSI’s control. Please note that any such statements are not guarantees of any future performance and that actual results or developments may differ materially from those projected in the forward-looking statements. Prepared by Wedbush Securities, Inc., a member of FINRA and SIPC. 1. WS makes a market in the securities of Abivax S.A..

Wedbush disclosure price charts are updated within the first fifteen days of each new calendar quarter per FINRA regulations. Price charts for companies initiated upon in the current quarter, and rating and target price changes occurring in the current quarter, will not be displayed until the following quarter. Additional information on recommended securities is available on request. Disclosure information regarding historical ratings and price targets is available: Research Disclosures Applicable disclosure information is also available upon request by contacting the Research Department at (212) 833-1375, by email to leslie.lippai@wedbush.com. You may also submit a written request to the following: Wedbush Securities, Attn: Research Department, 142 W 57th Street, New York, NY 10019. OTHER DISCLOSURES The information herein is based on sources that we consider reliable, but its accuracy is not guaranteed. The information contained herein is not a representation by this corporation, nor is any recommendation made herein based on any privileged information. This information is not intended to be nor should it be relied upon as a complete record or analysis: neither is it an offer nor a solicitation of an offer to sell or buy any security mentioned herein. This firm, Wedbush Securities, its officers, employees, and members of their families, or any one or more of them, and its discretionary and advisory accounts, may have a position in any security discussed herein or in related securities and may make, from time to time, purchases or sales thereof in the open market or otherwise. The information and expressions of opinion contained herein are subject to change without further notice. The herein mentioned securities may be sold to or bought from customers on a principal basis by this firm. Additional information with respect to the information contained herein may be obtained upon request. Wedbush Securities does and seeks to do business with companies covered in its research reports. Thus, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Retail Investors The information provided is for general informational purposes only and should not be considered an individual recommendation or personalized investment advice. The companies/investments mentioned may not be suitable for everyone. Each investor needs to review their own respective situation(s) before making any investment decisions. All expressions of opinion are subject to change without notice due to shifting market(s), economic or political conditions. Investment involves risks including the risk of principal. Past performance is no guarantee of future results and the opinions presented cannot be viewed as an indicator of future performance.

( Companies Mentioned: ABVX:NASDAQ, )

Abivax SA (ABVX) UC Opportunity: Oral Therapy Catalyst

Mon, 06 Jul 2026 00:00:00 PST

Source: Streetwise Reports 07/06/2026

Abivax SA (ABVX) advances obefazimod through Phase 3 success in ulcerative colitis with NDA filing targeted for late 2026. Learn why this oral miR-124 therapy stands out for investors now.

The market for treatments targeting chronic inflammatory conditions such as ulcerative colitis continues to expand as patients seek effective oral options that avoid injections or infusions. Abivax SA (ABVX:NASDAQ) is positioned to capture attention with its lead candidate that modulates the body's own regulatory pathways rather than broadly suppressing immunity.

Retail investors evaluating biotechnology names often look first at late-stage clinical progress and upcoming regulatory milestones. Abivax meets those criteria through positive data from its completed ABTECT program in ulcerative colitis, setting the stage for a potential New Drug Application filing.

Market Opportunity in Inflammatory Bowel Disease

Ulcerative colitis and Crohn's disease together represent a large and growing segment within immunology.

Patients with moderate to severe disease frequently cycle through multiple therapies, creating demand for new mechanisms that deliver durable responses with convenient dosing. An oral once-daily small molecule like obefazimod could address gaps left by existing injectable or infused treatments.

Why Abivax Stands Out

Founded in 2013 by immunologist Philippe Pouletty, the Paris-headquartered company maintains R&D operations in France and a U.S. office in Waltham, Massachusetts. Its sole clinical-stage asset, obefazimod (formerly ABX464), is the first molecule designed to increase expression of microRNA-124, a natural regulator that helps control inflammatory signaling. This differentiated approach may offer advantages in both efficacy and long-term safety compared with broader immunosuppressants.

Key Assets and Development Programs

Obefazimod has advanced furthest in ulcerative colitis. The pivotal Phase 3 ABTECT induction trials (ABTECT-1 and ABTECT-2) produced positive eight-week topline results in mid-2025. The 44-week maintenance portion delivered positive topline data on June 1, 2026, with both the 25-milligram and 50-milligram doses meeting the primary endpoint while maintaining a favorable safety profile.

A separate Phase 2b ENHANCE-CD trial in Crohn's disease began enrollment in the third quarter of 2024, with 12-week induction results expected in mid-2027. The company is also exploring additional candidates from its proprietary library of miR-124 enhancers.

Upcoming Catalysts and Regulatory Timeline

The most immediate value driver is the planned New Drug Application submission to the U.S. Food and Drug Administration for obefazimod in ulcerative colitis, targeted for late fourth quarter 2026 after a scheduled pre-NDA meeting. Additional milestones include topline Crohn's disease data in 2027 and potential selection of a combination therapy candidate by the end of 2026.

Key Investor Takeaways

Obefazimod's novel enhancement of microRNA-124 provides a differentiated mechanism in a competitive ulcerative colitis landscape.
Positive Phase 3 induction and maintenance data support an NDA filing targeted for late 2026, creating a clear regulatory catalyst.
Analyst price targets range from US$110 to CA$170, reflecting varied views on safety interpretation and commercial potential.
Institutional ownership near 50 percent signals professional investor interest, while retail investors still hold a meaningful portion of shares.
Expansion into Crohn's disease and follow-on miR-124 candidates offers longer-term pipeline optionality beyond the initial ulcerative colitis indication.

Analyst Perspectives and Valuation Views

Recent research notes highlight both enthusiasm and caution around the safety dataset. Laidlaw & Co. analyst Yale Jen reiterated a Buy rating and CA$160 12-month target, citing the innovative mechanism and de-risked induction results while viewing the stock as undervalued and a potential acquisition candidate. LifeSci Capital analyst Sam Slutsky maintained an Outperform rating and CA$170 target based on a DCF model projecting risk-adjusted peak sales of US$3.8 billion in ulcerative colitis and US$2.7 billion in Crohn's disease. Wedbush analyst David Nierengarten kept a Neutral rating but raised the target to US$110, noting ongoing questions about malignancy signals and the possibility of a boxed warning.

Other firms have adjusted targets in recent weeks. BTIG reiterated Buy and lifted its target to US$175, while Jefferies upgraded back to Buy with a US$158 target. Citizens and Truist Securities also reaffirmed positive ratings with targets between US$155 and US$187. These shifts illustrate how fresh maintenance data can influence sentiment even as some firms remain cautious on regulatory perception.

Share Structure and Ownership Profile

Abivax SA carries a market capitalization of US$11.6 billion with 79.29 million shares outstanding. The 52-week trading range spans US$6.20 to US$132.

¹Institutions hold 49.56 percent of shares, strategic investors own 5.3 percent, and the remainder is held by retail investors. [OWNERSHIP_CHART-11640]

Common Questions from Investors

Q: What is the primary endpoint met in the ABTECT maintenance trial? A: Both the 25-milligram and 50-milligram doses achieved the primary endpoint with a favorable safety profile at 44 weeks.

Q: When could obefazimod reach the U.S. market? A: The company targets an NDA submission in late 2026, which could lead to potential approval and launch in 2027 if the review proceeds smoothly.

Q: How does the company address malignancy concerns? A: Additional safety analyses using exposure-adjusted incidence rates showed no clear malignancy signal in part two of the maintenance study.

Q: What is the peak sales potential modeled by analysts? A: Models assume risk-adjusted global peak sales of approximately US$3.8 billion in ulcerative colitis and US$2.7 billion in Crohn's disease.

Q: Does Abivax have other assets beyond obefazimod? A: The company continues to research follow-on candidates from its proprietary library of miR-124 enhancers.

Abivax SA offers retail investors exposure to a late-stage oral therapy with a novel mechanism in a sizable inflammatory disease market. The upcoming NDA submission and additional clinical readouts provide defined milestones against which progress can be measured.

Important Disclosures:

Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

Disclosures for Laidlaw & Co., Abivax, June, 29, 2026:

ANALYST CERTIFICATION The analyst responsible for the content of this report hereby certifies that the views expressed regarding the company or companies and their securities accurately represent his/her personal views and that no direct or indirect compensation is to be received by the analyst for any specific recommendation or views contained in this report. Neither the author of this report nor any member of his immediate family or household maintains a position in the securities mentioned in this report. EQUITY DISCLOSURES For the purpose of ratings distributions, regulatory rules require the firm to assign ratings to one of three rating categories (i.e., Strong Buy/Buy-Overweight, Hold, or Underweight/Sell) regardless of a firm's own rating categories. Although the firm’s ratings of Buy/Overweight, Hold, or Underweight/Sell most closely correspond to Buy, Hold and Sell, respectively, the meanings are not the same because our ratings are determined on a relative basis against the analyst sector universe of stocks. An analyst's coverage sector is comprised of companies that are engaged in similar business or share similar operating characteristics as the subject company. The analysis sector universe is a sub-sector to the analyst's coverage sector, and is compiled to assist the analyst in determining relative valuations of subject companies. The composition of an analyst's sector universe is subject to change over time as various factors, including changing market conditions occur. Accordingly, the rating assigned to a particular stock represents solely the analyst's view of how that stock will perform over the next 12-months relative to the analyst's sector universe. Additional information available upon request.

ADDITIONAL DISCLOSURES As of the date of this report, neither the author of this report nor any member of his immediate family or household maintains an ownership position in the securities of the company (ies) mentioned in this report. This report does not provide individually tailored investment advice and has been prepared without regard to the individual financial circumstances and objectives of persons who receive it. Laidlaw & Co (UK), Ltd. recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. The securities, instruments, or strategies discussed in this report may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. This report is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. Associated persons of Laidlaw & Co (UK), Ltd not involved in the preparation of this report may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned herein and may trade them in ways different from those discussed in this report. While Laidlaw & Co (UK), Ltd., prohibits analysts from receiving any compensation. Bonus or incentive based on specific recommendations for, or view of, a particular company, investors should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. With the exception of information regarding Laidlaw & Co (UK), Ltd. this report is based on public information. Laidlaw & Co (UK), Ltd makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete and it should not be relied upon as such. Any opinions expressed are subject to change and Laidlaw & Co (UK), Ltd disclaims any obligation to advise you of changes in opinions or information or any discontinuation of coverage of a subject company. Facts and views presented in this report have not been reviewed by, and may not reflect information known to, professionals in other Laidlaw & Co (UK), Ltd business areas. Laidlaw & Co (UK), Ltd associated persons conduct site visits from time to time but are prohibited from accepting payment or reimbursement by the company of travel expenses for such visits. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices. market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments. Any trademarks and service marks contained in this report are the property of their respective owners. Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages of any kind relating to such data. This report or any portion thereof may not be reprinted, sold or redistributed without the written consent of Laidlaw & Co (UK), Ltd. This report is disseminated and available primarily electronically, and, in some cases, in printed form. The information and opinions in this report were prepared by Laidlaw & Co (UK), Ltd. For important disclosures, please see Laidlaw & Co (UK), Ltd.’s disclosure website at www.Laidlawltd.com, or contact your investment representative or Laidlaw & Co (UK), Ltd at 521 Fifth Ave, 12th Floor, New York, NY 10175 USA.

Disclosures for LifeSci Capital, Abivax, June 30, 2026:

Analyst Certification I, Sam Slutsky, certify that: (1) all of the views expressed in this report accurately reflect my personal views about any and all of the subject securities or subject companies, and (2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this report. I, Kate Dellorusso, certify that: (1) all of the views expressed in this report accurately reflect my personal views about any and all of the subject securities or subject companies, and (2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this report. DISCLOSURES An affiliate of LifeSci Capital LLC has provided non-investment banking securities-related services, non-securities services, and other products or services other than investment banking services to Abivax S.A. and received compensation for such services within the past 12 months. LifeSci Capital LLC or affiliates has managed or co-managed a public offering of securities for ABVX in the past 12 months. LifeSci Capital LLC or affiliates has received compensation for investment banking services from ABVX in the past 12 months. ABVX has been an investment banking client of LifeSci Capital LLC within the past 12 months.

This report has been prepared by LifeSci Capital LLC (“LSC”), solely for the purpose of supplying information to the clients of LSC and/or its affiliates to whom it is distributed. This report is not, and should not be construed as, a solicitation or offer to buy or sell any securities or related financial products. This report has been prepared by LSC solely from publicly available information. The information contained herein is believed to be reliable but has not been independently verified. LSC makes no guarantee, representation or warranty, and LSC and affiliates, directors, employees or agents accept no responsibility or liability whatsoever as to the accuracy, completeness or appropriateness of such information or for any loss or damage arising from the use or further communication of this report or any part of it. Information contained herein may not be current due to, among other things, changes in the financial markets or economic environment. Opinions reflected in this report are subject to change without notice. This report does not constitute and should not be used as a substitute for tax, legal or investment advice. The report has been prepared without regard to the individual financial circumstances, needs or objectives of persons who receive it. The securities and investments related to the securities discussed in this report may not be suitable for all investors and is intended for institutional investor use only. Readers should independently evaluate particular investments and strategies and seek the advice of a financial adviser before making any investment or entering into any transaction in relation to the securities mentioned in this report. An internal generative artificial intelligence (“AI”) tool may have been used in the preparation of this material, including assisting in fact-finding, data gathering and analysis, pattern recognition, and content drafting. Notwithstanding any such use of AI tools, this document has undergone human review prior to publishing. LSC has no legal responsibility to any investor who directly or indirectly receives this material. Investment decisions are to be made by and remain as the sole responsibility of the investor. Investment involves risks. The price of securities may go down as well as up, and under certain circumstances investors may sustain total loss of investment. Past performance should not be taken as an indication or guarantee of future performance. Unless otherwise attributed, forecasts of future performance represent analysts’ estimates based on factors they consider relevant. Actual performance may vary. Consequently, no express or implied warranty can be made regarding future performance. The authors of this report are prohibited from using any material, non-public or insider information.

LSC has policies and procedures, which include, without limitation, independence policies and permanent information barriers, that are intended, and upon which LSC relies, to manage potential conflicts of interest and control the flow of information within departments of LSC and among its affiliates. LSC does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. LSC or other companies affiliated with LSC, together with their respective directors and officers, may have or take positions in the securities mentioned in this report, or derivatives of such securities or other securities issued by companies mentioned in this report, for their own account or the accounts of others, or enter into transactions contrary to any recommendations contained herein, and also may perform or seek to perform broking and other investment or securities related services for the companies mentioned in this report as well as other parties generally. Please visit https://lifesci.bluematrix.com/sellside/Disclosures.action for disclosures related to each company that is a subject of this report. Alternatively, please contact us by telephone at (646) 876-5059 or by mail at LifeSci Capital LLC, Attn: Compliance, 1700 Broadway, 40th Floor, New York, NY 10019 to obtain disclosures relating to any of the companies that are the subject of this report. Restrictions on Distribution This report is not directed to, or intended for distribution to or use by, any person who is a citizen or resident of, or entity located in, any locality, territory, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to or restricted by law or regulation. Persons or entities into whose possession this report comes should inform themselves about and observe such restrictions. United States: LifeSci Capital LLC, 1700 Broadway, 40th Floor, New York, NY 10019, USA, contact number +1-646-847-1400, distributes or approves the distribution of this report in the United States and takes responsibility for it. Any transaction by a US investor resulting from the information contained in this report may be affected only through LSC. Interested US investors should contact their LSC sales representative. © LifeSci Capital LLC. All Rights Reserved 2026. This document may not be altered, reproduced (including for purposes of training artificial intelligence models or tools), redistributed, passed on to any other party or used to create derivative works, in whole or in part, without the prior written consent of LifeSci Capital, LLC.

Disclosures for Webush, Abivax, June 30, 2026:

Analyst Certification: We, David Nierengarten, Martin Fan and Dennis Pak, certify that the views expressed in this report accurately reflect our personal opinions and that we have not and will not, directly or indirectly, receive compensation or other payments in connection with our specific recommendations or views contained in this report.

( Companies Mentioned: ABVX:NASDAQ, )

How Do Analysts Rate This Biotech Focused on Chronic Inflammatory Diseases?

Mon, 06 Jul 2026 00:00:00 PST

Source: Streetwise Reports 07/06/2026

Find out what analysts think of clinical-stage biotech Abivax SA (ABVX:NASDAQ), which is focusing on harnessing the immune response in patients with chronic inflammatory diseases.

Abivax SA (ABVX:NASDAQ) is a clinical-stage biotechnology company headquartered in Paris that focuses on therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.

The company, founded in 2013 by French immunologist Philippe Pouletty, has R&D operations in France and a U.S. office in Waltham, Massachusetts.

Its lead and only clinical-stage asset is obefazimod (formerly ABX464), an oral, once-daily small molecule and the first drug of its kind designed to enhance expression of microRNA-124 (miR-124), a naturally occurring regulator of inflammation. Obefazimod is furthest along in ulcerative colitis (UC), where it has completed the pivotal Phase 3 ABTECT program: positive topline results from the eight-week induction trials (ABTECT-1 and ABTECT-2) were announced in mid-2025, and positive topline results from the 44-week maintenance trial were announced June 1, 2026, with both the 25- and 50-milligram doses meeting the primary endpoint and showing a favorable safety profile.

Separately, obefazimod is in earlier-stage development for Crohn's disease under the ENHANCE-CD program, a Phase 2b trial that began enrolling patients in Q3 2024; 12-week induction data are expected mid-2027. Abivax is also researching potential follow-on drug candidates from its proprietary library of miR-124 enhancers.

The company's most significant near-term catalyst is a planned NDA submission to the FDA for obefazimod in ulcerative colitis, targeted for late Q4 2026, following a pre-NDA meeting with the agency.

¹From the following analysts' ratings, Street Smart came up with an average rating of Buy / Overweight / Outperform / Neutral and an average target price of US$152.79 / CA$216.94.

Yale Jen — Laidlaw & Co.

Abivax SA recently shared additional findings from part two of the obefazimod in UC ABTECT maintenance study, providing further insights, particularly concerning the safety profile of the treatment, noted Laidlaw & Co. Analyst Yale Jen in a June 29 note.

The company's analysis has reinforced the potential of obefazimod as a leading oral treatment for ulcerative colitis (UC), boasting impressive efficacy and a well-received safety profile. The approach to evaluating the safety data concerning non-melanoma skin cancers (NMSC) and other malignancies through exposure-adjusted incidence rates is seen as a logical and rational method to assess their impact on safety.

With the innovative mechanism of action (MOA) and compelling de-risked data from the obefazimod induction study in ulcerative colitis (UC), along with forthcoming maintenance study results, ABVX shares are currently perceived as undervalued and increasingly appealing as a potential acquisition target for major pharmaceutical companies.

"We are reiterating our Buy rating and CA$160 12-month price target," wrote Jen. CA$160 would be a 66% return at the time of writing. "Our valuation is based on blended value from forward P/E and NPV-driven sum-of-the-parts analyses."

Continuing from previous discussions, ABVX has indicated that a boxed warning for obefazimod in UC treatment seems highly unlikely based on the study outcomes. The next significant milestone for ABVX is a pre-NDA meeting with the FDA, scheduled for July 30.

Sam Slutsky — LifeSci Capital

Abivax conducted a conference call to discuss the findings from part two of its ABTECT maintenance study on obefazimod, which involved patients with moderate-to-severely active ulcerative colitis (UC) who either did not respond during the induction phase or lost response during the part one maintenance phase, according to a June 30 research note by LifeSci Capital Analyst Sam Slutsky.

The additional safety data presented in this phase appeared to mitigate market concerns regarding the higher incidence of cancer cases observed in the 50-milligram obefazimod cohort compared to the 25 mg and placebo groups in the earlier part one data, as no clear malignancy signal was evident in part two. This data also reinforced Abivax's strong efficacy profile, the analyst wrote.

The stock was rated Outperform by the analyst, who said the valuation methodology for a CA$170 price target was based on a DCF model through 2041, assuming an 8% discount rate, and a 0% terminal growth rate. That would mean a 77% return at the time he wrote the note.

The model anticipates obefazimod entering the market for moderate to severe UC in 2027, achieving global peak sales of US$4.2 billion (risk-adjusted to US$3.8 billion). The model also assumes a 90% probability of success and forecasts a 15% peak penetration rate among moderate to severe UC patients in the US receiving advanced therapy. For Crohn's disease, a launch is anticipated in 2031, with peak global sales reaching US$3.6 billion (risk-adjusted to US$2.7 billion), and a 75% probability of success, modeling a 10% peak penetration rate.

Key risks to the 12-month price target include poorer-than-expected clinical outcomes with obefazimod in UC or Crohn's disease, potential issues with extending the IP of obefazimod, unexpected competition in the IBD market, drug pricing pressures, regulatory changes, market downturns, and the possibility of dilutive financings.

David Nierengarten — Wedbush

Analyst David Nierengarten of Wedbush also commented on the same news in a June 30 research note.

He noted that the 50-milligram dosage of obefazimod, which showed the highest efficacy, also reported the highest number of malignancies. Concerns persist about how the FDA might perceive the cancer risk associated with obefazimod, and there is ongoing speculation about the potential for a Black Box warning. Such a warning could significantly impact obefazimod's market differentiation compared to JAK inhibitors and negatively affect its positioning against emerging IBD treatments like TL1A inhibitors.

Looking ahead, key milestones for ABVX include topline data from the Phase 2 ENHANCE-CD study of obefazimod for Crohn's disease by mid-2027, an FDA NDA submission for obefazimod in UC by the fourth quarter of 2026, and the selection of an IBD combo therapy candidate by the end of 2026.

"We reiterate our NEUTRAL rating and increase our PT (price target) to US$110 (from US$90)," Nierengarten wrote. "Our PT is derived from a sum-of-parts valuation for each of the company's clinical programs: a DCF valuation of 2028-39E ww sales of obefazimod in UC and CD (discounted back by 15-25%). Changes to our model are from accelerating our launch trajectory."[OWNERSHIP_CHART-11640]

More Analyst Ratings

According to Benzinga, analyst sentiment on Abivax SA shifted several times over the past month. On June 2, BTIG reiterated a Buy rating with a US$150 price target, while Citizens raised its price target from US$131 to US$187, keeping its Outperform rating. Morgan Stanley maintained its Overweight rating but trimmed its target from US$145 to US$132, and Jefferies downgraded the stock from Buy to Hold, cutting its price target from US$160 to US$90. Truist Securities kept its Buy rating but lowered its target from US$140 to US$135.

Sentiment then began improving: BTIG reiterated Buy on June 16 and raised its target from US$150 to US$175 on June 30, the same day Leerink Partners maintained Outperform and raised its target from US$140 to US$148, and Jefferies reversed course, upgrading from Hold back to Buy and lifting its target from US$108 to US$158.

The rally in analyst confidence continued into July. On July 1, 2026, Citizens reiterated its Outperform rating with a US$187 price target, and on July 2, Truist Securities reaffirmed its Buy rating while raising its price target from US$135 to US$155.

Ownership and Share Structure²

Abivax S.A. has a market cap of US$11.6 billion billion, with 79.29 million shares outstanding. The company's 52-week range is US$6.20-US$132.

Institutions own 49.56% of shares, while Strategic Investors own 5.3%. The remaining shares are held by Retail.

Important Disclosures:

Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Street Smart Average Price Target Formula

Street Smart Consulting has attained an average price target and rating for this company from our system's formula. The system calculates an average of all analyst target prices, which are originally in Canadian or U.S. dollars, then converts them to both dollar amounts. For the recommendation, it selects whichever rating (Buy, Sell, Hold, etc.) appears most frequently among analysts. When there's a tie for the most common recommendation, all tied ratings are included.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

Disclosures for Laidlaw & Co., Abivax, June, 29, 2026:

Disclosures for LifeSci Capital, Abivax, June 30, 2026:

Disclosures for Webush, Abivax, June 30, 2026:

( Companies Mentioned: ABVX:NASDAQ, )

The Life Sciences Report

Novocure Posts Record Q2 Revenue of US$183.6M

Key Takeaways

Optune Pax Earns European Approval

Cancer Cases Rise, Treatment Costs Climb

Neutral or Buy?

FDA Brain Metastases Decision Due Q4

Ownership & Share Information1

Frequently Asked Questions

US-Listed Rare Disease Biotech Hit With Full Clinical Hold; Data Unblinding Ahead

Clinical Hold and Planned Data Unblinding

Development Timeline Impact

Financial Position and Estimates

Valuation and Risks

Antibacterial Drug Partnership Accelerates PolyPid Commercial Path

Pharma Market Opportunity Sets Stage for Specialized Therapies

Why PolyPid Stands Out Through Strategic Partnership

Unique Business Model and Key Catalysts

Key Investor Takeaways

Analyst Views and Upcoming Regulatory Timeline

Share Structure and Ownership Details

Common Questions from Investors

Biotech Advances VOXZOGO Toward Landmark US FDA Approval

More than 80% of Affected Children Born to Average-Height Parents

Therapy Converting From Accelerated to Traditional Approval

Co. Holds Advantage Over Competitors, Analyst Says

The Catalyst: Diagnostic Methods More Accurate

Ownership and Share Information1

Common Investor Questions

Satellos Bioscience Delivers Promising DMD Data With Fast Track Win

Why the Latest Data Matters for Investors

Key Investor Takeaways

Fast Track Designation Accelerates Path Forward

Analyst and Market Reaction

Market Opportunity Supports Long-Term Growth

Ownership Structure and Upcoming Milestones1

Common Questions from Investors

Biotech With Muscle Disease Drug Uncovers Results in Trial Data

Treatment Receives Fast Track Designation

Report: Analyst Says Results Are 'Impressive'

'MSLE Delivered!'

The Catalyst: Increase in Cases to Lead to Market Growth

Ownership and Share Information1

NASDAQ-Listed Duchenne Muscular Dystrophy Drugmaker Wins FDA Filing Acceptance Despite Confirmatory Trial Miss

Filing Acceptance Seen as Procedural, Not a Regulatory Signal

ESSENCE Endpoint Miss Remains the Core Overhang

Revenue Trajectory and Financial Metrics

Valuation and Risks

Grey Matters Health Inc. Targets Alzheimer's PET Imaging Opportunity

Alzheimer's Diagnostics Market Opportunity

Why Grey Matters Health Stands Out

Key Investor Takeaways

Unique Business Model and Technology Advantage

Industry Timing and Trends

Analyst Views and Valuation

Clinic Opening and Operational Milestones

Share Structure and Ownership

Common Questions from Investors

BioLargo (BLGO) Aligns CEO Pay With Growth as Contracts Renew

Why BioLargo Stands Out for Retail Investors

Leadership Alignment and Capital Structure

Key Investor Takeaways

Strategic Partnerships Accelerating Commercialization

Analyst Perspectives on Technology Portfolio

Market Timing and Growth Drivers

Ownership and Share Structure

Common Questions from Investors

Digital Health Platform Lands Access to Hundreds of Thousands of Covered Lives

Chronic Care Drives Digital Health Adoption

Analyst Perspective: Commercial Execution and Platform Expansion Remained the Focus

Channel Expansion and Multi-Condition Strategy

Ownership and Share Information1

First-of-Its-Kind US Brain Imaging Clinic Takes Delivery of Key PET Scanner

Alzheimer's Diagnostics Market Continues to Evolve

Analyst Commentary on Alzheimer's Disease Imaging

Clinic Opening and Operational Milestones

Ownership and Share Structure2

Bullish Charts and Commercial Breakthroughs For Florida Biomanufacturer Could Fuel Upwards Valuation

Biotech: A Bullish Market Sector

Commercial Momentum and Platform Validation

Ownership & Share Information¹

Ownership Structure and Upcoming Milestones¹

Ownership and Share Information¹

Ownership and Share Information¹

Ownership and Share Structure²

Ownership and Share Structure²